2022 April AANnews

VOLUME 34 · ISSUE 4 · APRIL 2022

Visit AAN.com/Covid19 for the latest pandemic information and resources to support you and your crucial work.

REGISTRATION OPENS LATER THIS MONTH FOR NEW SUMMER CONFERENCE Autoimmune Neurology and Neurology Year in Review A new AAN-hosted conference is coming this July 15 through 16 to the San Francisco Marriott Marquis—and registration opens later this month. The AAN Summer Conference: Autoimmune Neurology and Neurology Year in Review will offer a unique opportunity for those seeking the latest updates in the science and education of autoimmune neurology to come together to learn through a variety of styles including didactic lectures, hands-on experiences, casebased presentations, and more. The robust two-day program will include autoimmune neurology programming led by directors Anastasia Zederidou, MD, of the Mayo Clinic in Rochester, MN, and Stacey Clardy, MD, PhD, FAAN, of the University of Utah. In addition, Nicole Beaton Sur, MD, of the University of Miami will direct the Neurology Year in Review portion of the program.

Continued on page 29

San Francisco 2022

›

COVID-19 and Safety

Because of our commitment to creating a safe and healthy environment for participants, all in-person attendees, exhibitors, press personnel, guests, and staff must complete the COVID-19 vaccination process with an acceptable vaccine and booster, if eligible, a minimum of seven days prior to the event; provide verification of full COVID-19 vaccination status; and wear a mask indoors.

There’s Still Time to Register for the Upcoming Virtual Annual Meeting

AAN Action on Ukraine Crisis

The exciting 2022 Annual Meeting virtual option will be taking place this April 24 through 26 following the in-person Annual Meeting in Seattle—and there’s still time to take advantage of this convenient, distinct learning and networking opportunity! Visit AAN.com/AM today to secure your spot for the virtual Annual Meeting which will offer a fresh lineup of top-tier education, valuable CME, science, and networking opportunities.

Continued on page 29

12 New Brain & Life Podcast Debuts

›

In response to the tragic crisis in Ukraine, the AAN quickly assembled in March an AAN Ukraine Crisis Response Work Group, headed by Lyell K. Jones, Jr., MD, FAAN, to develop plans to assist neurologists in the region and provide tools to support care of neurology patients who have been displaced. AAN President Orly Avitzur, MD, MBA, FAAN, personally reached out to all 34 AAN members in Ukraine and through Neurology Today® shares some of their stories and calls out organizations where donations can be sent.

Visit AAN.com/Ukraine to learn more.

18 Free AAN Anti-racism Education Program Opens to Members

20 Celebrate These 2022

AAN Award Recipients

FOR PATIENTS WITH RELAPSING FORMS OF MS

PLAYING WITH FEWER RELAPSES • The efficacy of VUMERITY® (diroximel fumarate) is based upon bioavailability studies in patients with relapsing forms of multiple sclerosis and healthy subjects comparing dimethyl fumarate to VUMERITY1 • Study 1: A 2-year, randomized, double-blind, placebo-controlled study in 1234 patients with RRMS. Primary endpoint: PPR1 • Study 2: A 2-year, multicenter, randomized, double-blind, placebo-controlled study in 1417 patients with RRMS. Primary endpoint: ARR1

VUMERITY offers the efficacy demonstrated by dimethyl fumarate across 2 pivotal trials1

of treated patients were relapse-free at 2 years1

• Dimethyl fumarate demonstrated a 49% and 34% relative risk reduction in PPR vs placebo, respectively (27% vs 46%; P<0.0001), (29% vs 41%; P=0.0020)

Based on ARR, treated patients experienced

RELAPSE every 2 years1

• Dimethyl fumarate demonstrated a 53% and 44% relative reduction in ARR vs placebo, respectively (0.172 vs 0.364; P<0.0001), (0.224 vs 0.401; P<0.0001)

Visit www.vumerityhcp.com

Indication VUMERITY® (diroximel fumarate) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Important Safety Information CONTRAINDICATIONS

VUMERITY is contraindicated in patients • With known hypersensitivity to diroximel fumarate, dimethyl fumarate, or to any of the excipients of VUMERITY. Reactions may include anaphylaxis and angioedema • Taking dimethyl fumarate

WARNINGS AND PRECAUTIONS

Anaphylaxis and Angioedema • VUMERITY can cause anaphylaxis and angioedema after the first dose or at any time during treatment. Signs and symptoms in patients taking dimethyl fumarate (which has the same active metabolite as VUMERITY) have included difficulty breathing, urticaria, and swelling of the throat and tongue. Patients should be instructed to discontinue VUMERITY and seek immediate medical care should they experience signs and symptoms of anaphylaxis or angioedema

Progressive Multifocal Leukoencephalopathy • Progressive multifocal leukoencephalopathy (PML) has occurred in patients with MS treated with dimethyl fumarate (which has the same active metabolite as VUMERITY). PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. A fatal case of PML occurred in a patient who received dimethyl fumarate for 4 years while enrolled in a clinical trial • PML has occurred in patients taking dimethyl fumarate in the postmarketing setting in the presence of lymphopenia (<0.9 × 109/L). While the role of lymphopenia in these cases is uncertain, the PML cases have occurred predominantly in patients with lymphocyte counts <0.8×109/L persisting for more than 6 months • At the first sign or symptom suggestive of PML, withhold VUMERITY and perform an appropriate diagnostic evaluation.

Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes

Important Safety Information (cont'd) WARNINGS AND PRECAUTIONS (CONT'D)

Progressive Multifocal Leukoencephalopathy (cont'd) • Magnetic resonance imaging (MRI) findings may be apparent before clinical signs or symptoms. Monitoring with MRI for signs consistent with PML may be useful, and any suspicious findings should lead to further investigation to allow for an early diagnosis of PML, if present Herpes Zoster and Other Serious Opportunistic Infections • Serious cases of herpes zoster have occurred in patients treated with dimethyl fumarate (which has the same active metabolite as VUMERITY), including disseminated herpes zoster, herpes zoster ophthalmicus, herpes zoster meningoencephalitis, and herpes zoster meningomyelitis. These events may occur at any time during treatment. Monitor patients on VUMERITY for signs and symptoms of herpes zoster. If herpes zoster occurs, appropriate treatment for herpes zoster should be administered • Other serious opportunistic infections have occurred with dimethyl fumarate, including cases of serious viral (herpes simplex virus, West Nile virus, cytomegalovirus), fungal (Candida and Aspergillus), and bacterial (Nocardia, Listeria monocytogenes, Mycobacterium tuberculosis) infections. These infections have been reported in patients with reduced absolute lymphocyte counts (ALC) as well as in patients with normal ALC. These infections have affected the brain, meninges, spinal cord, gastrointestinal tract, lungs, skin, eye, and ear. Patients with symptoms and signs consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment • Consider withholding VUMERITY treatment in patients with herpes zoster or other serious infections until the infection has resolved Lymphopenia • VUMERITY may decrease lymphocyte counts. In the MS placebo-controlled trials with dimethyl fumarate (which has the same active metabolite as VUMERITY), mean lymphocyte counts decreased by approximately 30% during the first year of treatment with dimethyl fumarate and then remained stable.

Four weeks after stopping dimethyl fumarate, mean lymphocyte counts increased but did not return to baseline. The incidence of infections and serious infections was similar in patients treated with dimethyl fumarate or placebo. There was no increased incidence of serious infections observed in patients with lymphocyte counts <0.8 x 109/L or ≤0.5 x 109/L in controlled trials, although one patient in an extension study developed PML in the setting of prolonged lymphopenia (lymphocyte counts predominantly <0.5 x 109/L for 3.5 years) • In controlled and uncontrolled clinical trials with dimethyl fumarate, 2% of patients experienced lymphocyte counts <0.5 x 109/L for at least six months, and in this group the majority of lymphocyte counts remained <0.5 x 109/L with continued therapy. Neither VUMERITY nor dimethyl fumarate have been studied in patients with preexisting low lymphocyte counts • Obtain a complete blood count (CBC), including lymphocyte count, before initiating treatment with VUMERITY, 6 months after starting treatment, and then every 6 to 12 months thereafter, and as clinically indicated. Consider interruption of VUMERITY in patients with lymphocyte counts less than 0.5 x 109/L persisting for more than six months. Given the potential for delayed recovery of lymphocyte counts, continue to obtain lymphocyte counts until their recovery if VUMERITY is discontinued or interrupted because of lymphopenia. Consider withholding treatment from patients with serious infections until resolution Liver Injury • Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate (which has the same active metabolite as VUMERITY) in the postmarketing setting.

The onset has ranged from a few days to several months after initiation of treatment with dimethyl fumarate. Signs and symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal and elevation of total bilirubin to greater than 2-fold the upper limit of normal have been observed. These abnormalities © 2021 Biogen. All rights reserved. 07/21 VUM-US-0458 v4

resolved upon treatment discontinuation. Some cases required hospitalization. None of the reported cases resulted in liver failure, liver transplant, or death. However, the combination of new serum aminotransferase elevations with increased levels of bilirubin caused by drug-induced hepatocellular injury is an important predictor of serious liver injury that may lead to acute liver failure, liver transplant, or death in some patients • Elevations of hepatic transaminases (most no greater than 3 times the upper limit of normal) were observed during controlled trials with dimethyl fumarate • Obtain serum aminotransferase, alkaline phosphatase (ALP), and total bilirubin levels prior to treatment with VUMERITY and during treatment as clinically indicated. Discontinue VUMERITY if clinically significant liver injury induced by VUMERITY is suspected Flushing • VUMERITY may cause flushing (e.g., warmth, redness, itching, and/or burning sensation). In clinical trials of dimethyl fumarate (which has the same active metabolite as VUMERITY), 40% of dimethyl fumarate-treated patients experienced flushing. Flushing symptoms generally began soon after initiating dimethyl fumarate and usually improved or resolved over time. In the majority of patients who experienced flushing, it was mild or moderate in severity. Three percent (3%) of patients discontinued dimethyl fumarate for flushing and <1% had serious flushing symptoms that were not life-threatening but led to hospitalization

ADVERSE REACTIONS • The most common adverse reactions (incidence ≥10% and ≥2% more than placebo) for dimethyl fumarate (which has the same active metabolite as VUMERITY) were flushing, abdominal pain, diarrhea, and nausea • Gastrointestinal adverse reactions: Dimethyl fumarate caused GI events (e.g., nausea, vomiting, diarrhea, abdominal pain, and dyspepsia). The incidence of GI events was higher early in the course of treatment (primarily in month 1) and usually decreased over time in patients treated with dimethyl fumarate compared with placebo. Four percent (4%) of patients treated with dimethyl fumarate and less than 1% of placebo patients discontinued due to gastrointestinal events. The incidence of serious GI events was 1% in patients treated with dimethyl fumarate • Hepatic transaminases: An increased incidence of elevations of hepatic transaminases in patients treated with dimethyl fumarate was seen primarily during the first six months of treatment and most patients with elevations had levels <3 times the upper limit of normal (ULN) during controlled trials. There were no elevations in transaminases ≥ 3 times the ULN with concomitant elevations in total bilirubin >2 times the ULN. Discontinuations due to elevated hepatic transaminases were <1% and were similar in patients treated with dimethyl fumarate or placebo • Eosinophilia adverse reactions: A transient increase in mean eosinophil counts was seen during the first 2 months of therapy

USE IN SPECIFIC POPULATIONS

Renal Impairment • No dosage adjustment is necessary in patients with mild renal impairment. Because of an increase in the exposure of a major metabolite, use of VUMERITY is not recommended in patients with moderate or severe renal impairment Please see following pages for Brief Summary of full Prescribing Information.

PPR=proportion of patients relapsed; ARR=annualized relapse rate.

Reference: 1. VUMERITY Prescribing Information, Biogen, Cambridge, MA.

VUMERITY® (diroximel fumarate) delayed-release capsules, for oral use Brief Summary of full Prescribing Information 1. INDICATIONS AND USAGE VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsingremitting disease, and active secondary progressive disease, in adults.

2. DOSAGE AND ADMINISTRATION 2.1 Blood Tests Prior to Initiation of VUMERITY Obtain the following prior to treatment with VUMERITY: • A complete blood cell count (CBC), including lymphocyte count [see Warnings and Precautions (5.4)] • Serum aminotransferase, alkaline phosphatase, and total bilirubin levels [see Warnings and Precautions (5.5)] 2.2 Dosing Information The starting dosage for VUMERITY is 231 mg twice a day orally. After 7 days, the dosage should be increased to the maintenance dosage of 462 mg (administered as two 231 mg capsules) twice a day orally.

Temporary dosage reductions to 231 mg twice a day may be considered for individuals who do not tolerate the maintenance dosage. Within 4 weeks, the recommended dosage of 462 mg twice a day should be resumed. Discontinuation of VUMERITY should be considered for patients unable to tolerate return to the maintenance dosage.

Administration of non-enteric coated aspirin (up to a dose of 325 mg) 30 minutes prior to VUMERITY dosing may reduce the incidence or severity of flushing [see Clinical Pharmacology (12.3)].

2.3 Administration Instructions Swallow VUMERITY capsules whole and intact. Do not crush or chew, or sprinkle the capsule contents on food.

If taken with food, avoid a high-fat, high-calorie meal/snack; the meal/snack should contain no more than 700 calories and no more than 30 g fat [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3)].

Avoid co-administration of VUMERITY with alcohol [see Clinical Pharmacology (12.3)].

of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. A fatal case of PML occurred in a patient who received dimethyl fumarate for 4 years while enrolled in a clinical trial.

During the clinical trial, the patient experienced prolonged lymphopenia (lymphocyte counts predominantly <0.5 × 109/L for 3.5 years) while taking dimethyl fumarate [see Warnings and Precautions (5.4)]. The patient had no other identified systemic medical conditions resulting in compromised immune system function and had not previously been treated with natalizumab, which has a known association with PML. The patient was also not taking any immunosuppressive or immunomodulatory medications concomitantly.

PML has also occurred in patients taking dimethyl fumarate in the postmarketing setting in the presence of lymphopenia (<0.9 × 109/L).

While the role of lymphopenia in these cases is uncertain, the PML cases have occurred predominantly in patients with lymphocyte counts <0.8×109/L persisting for more than 6 months.

At the first sign or symptom suggestive of PML, withhold VUMERITY and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.

Magnetic resonance imaging (MRI) findings may be apparent before clinical signs or symptoms. Cases of PML diagnosed based on MRI findings and the detection of JCV DNA in the cerebrospinal fluid in the absence of clinical signs or symptoms specific to PML, have been reported in patients treated with other MS medications associated with PML. Many of these patients subsequently became symptomatic with PML. Therefore, monitoring with MRI for signs that may be consistent with PML may be useful, and any suspicious findings should lead to further investigation to allow for an early diagnosis of PML, if present.

Lower PML-related mortality and morbidity have been reported following discontinuation of another MS medication associated with PML in patients with PML who were initially asymptomatic compared to patients with PML who had characteristic clinical signs and symptoms at diagnosis. It is not known whether these differences are due to early detection and discontinuation of MS treatment or due to differences in disease in these patients.

2.4 Blood Tests to Assess Safety After Initiation of VUMERITY Obtain a complete blood cell count (CBC), including lymphocyte count, 6 months after initiation of VUMERITY and then every 6 to 12 months 5.3 Herpes Zoster and Other Serious Opportunistic Infections thereafter, as clinically indicated [see Warnings and Precautions (5.4)].

Serious cases of herpes zoster have occurred in patients treated Obtain serum aminotransferase, alkaline phosphatase, and total with dimethyl fumarate (which has the same active metabolite as bilirubin levels during treatment with VUMERITY, as clinically indicated VUMERITY) including disseminated herpes zoster, herpes zoster ophthalmicus, herpes zoster meningoencephalitis, and herpes zoster [see Warnings and Precautions (5.5)]. meningomyelitis. These events may occur at any time during treatment.

2.5 Patients With Renal Impairment Monitor patients on VUMERITY for signs and symptoms of herpes No dosing adjustment is recommended in patients with mild renal zoster. If herpes zoster occurs, appropriate treatment for herpes zoster impairment. should be administered.

VUMERITY is not recommended in patients with moderate or severe Other serious opportunistic infections have occurred with dimethyl renal impairment [see Use in Specific Populations (8.6) and Clinical fumarate, including cases of serious viral (herpes simplex virus, Pharmacology (12.3)].

West Nile virus, cytomegalovirus), fungal (Candida and Aspergillus), and bacterial (Nocardia, Listeria monocytogenes, Mycobacterium 3. DOSAGE FORMS AND STRENGTHS These infections have been reported in VUMERITY is available as hard, delayed-release capsules containing tuberculosis) infections.

231 mg of diroximel fumarate. The capsules have a white cap and a patients with reduced absolute lymphocyte counts (ALC) as well as in patients with normal ALC. These infections have affected the brain, white body, printed with “DRF 231 mg” in black ink on the body. meninges, spinal cord, gastrointestinal tract, lungs, skin, eye, and 4. CONTRAINDICATIONS ear. Patients with symptoms and signs consistent with any of these VUMERITY is contraindicated in patients infections should undergo prompt diagnostic evaluation and receive • With known hypersensitivity to diroximel fumarate, dimethyl appropriate treatment. fumarate, or to any of the excipients of VUMERITY. Reactions Consider withholding VUMERITY treatment in patients with herpes may include anaphylaxis and angioedema [see Warnings and zoster or other serious infections until the infection has resolved [see Precautions (5.1)].

Adverse Reactions (6.2)].

• Taking dimethyl fumarate [see Drug Interactions (7.1)].

5.4 Lymphopenia 5. WARNINGS AND PRECAUTIONS VUMERITY may decrease lymphocyte counts. In the MS placebo5.1 Anaphylaxis and Angioedema controlled trials with dimethyl fumarate (which has the same active VUMERITY can cause anaphylaxis and angioedema after the first metabolite as VUMERITY), mean lymphocyte counts decreased by dose or at any time during treatment. Signs and symptoms in patients approximately 30% during the first year of treatment with dimethyl taking dimethyl fumarate (which has the same active metabolite as fumarate and then remained stable. Four weeks after stopping dimethyl VUMERITY) have included difficulty breathing, urticaria, and swelling fumarate, mean lymphocyte counts increased but did not return to of the throat and tongue. Patients should be instructed to discontinue baseline. Six percent (6%) of dimethyl fumarate patients and <1% of VUMERITY and seek immediate medical care should they experience placebo patients experienced lymphocyte counts <0.5 × 109/L (lower signs and symptoms of anaphylaxis or angioedema. limit of normal 0.91 × 109/L). The incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with 5.2 Progressive Multifocal Leukoencephalopathy Progressive multifocal leukoencephalopathy (PML) has occurred in dimethyl fumarate or placebo, respectively. There was no increased infections observed in patients with lymphocyte patients with MS treated with dimethyl fumarate (which has the same incidence of serious 9 9 active metabolite as VUMERITY). PML is an opportunistic viral infection counts <0.8 × 10 /L or ≤0.5 × 10 /L in controlled trials, although one

patient in an extension study developed PML in the setting of prolonged lymphopenia (lymphocyte counts predominantly <0.5 × 109/L for 3.5 years) [see Warnings and Precautions (5.2)].

In controlled and uncontrolled clinical trials with dimethyl fumarate, 2% of patients experienced lymphocyte counts <0.5 × 109/L for at least six months, and in this group the majority of lymphocyte counts remained <0.5 × 109/L with continued therapy. Neither VUMERITY® (diroximel fumarate) nor dimethyl fumarate have been studied in patients with preexisting low lymphocyte counts.

Obtain a complete blood count (CBC), including lymphocyte count, before initiating treatment with VUMERITY, 6 months after starting treatment, and then every 6 to 12 months thereafter, and as clinically indicated. Consider interruption of VUMERITY in patients with lymphocyte counts less than 0.5 × 109/L persisting for more than six months. Given the potential for delayed recovery of lymphocyte counts, continue to obtain lymphocyte counts until their recovery if VUMERITY is discontinued or interrupted because of lymphopenia.

Consider withholding treatment from patients with serious infections until resolution. Decisions about whether or not to restart VUMERITY should be individualized based on clinical circumstances.

The data described in the following sections were obtained using dimethyl fumarate delayed-release capsules, which has the same active metabolite as VUMERITY. Adverse Reactions in Placebo-Controlled Trials with Dimethyl Fumarate In the two well-controlled studies demonstrating effectiveness, 1529 patients received dimethyl fumarate with an overall exposure of 2244 person-years [see Clinical Studies (14)].

The adverse reactions presented in Table 1 below are based on safety information from 769 patients treated with dimethyl fumarate 240 mg twice a day and 771 placebo-treated patients. The most common adverse reactions (incidence ≥10% and ≥2% more than placebo) for dimethyl fumarate were flushing, abdominal pain, diarrhea, and nausea.

Table 1: Adverse Reactions in Study 1 and 2 Reported for Dimethyl Fumarate at ≥2% Higher Incidence than Placebo

Adverse Reactions

Dimethyl Fumarate 240 mg Twice Daily (N=769) %

Placebo (N=771)%

5.5 Liver Injury Clinically significant cases of liver injury have been reported in patients 40 6 treated with dimethyl fumarate (which has the same active metabolite Flushing as VUMERITY) in the postmarketing setting. The onset has ranged Abdominal pain 18 10 from a few days to several months after initiation of treatment with 14 11 dimethyl fumarate. Signs and symptoms of liver injury, including Diarrhea elevation of serum aminotransferases to greater than 5-fold the upper Nausea 12 9 limit of normal and elevation of total bilirubin to greater than 2-fold Vomiting 9 5 the upper limit of normal have been observed. These abnormalities resolved upon treatment discontinuation. Some cases required Pruritus 8 4 hospitalization. None of the reported cases resulted in liver failure, Rash 8 3 liver transplant, or death. However, the combination of new serum 6 4 aminotransferase elevations with increased levels of bilirubin caused Albumin urine present by drug-induced hepatocellular injury is an important predictor of Erythema 5 1 serious liver injury that may lead to acute liver failure, liver transplant, Dyspepsia 5 3 or death in some patients.

Elevations of hepatic transaminases (most no greater than 3 times Aspartate aminotransferase 4 2 the upper limit of normal) were observed during controlled trials with increased dimethyl fumarate [see Adverse Reactions (6.1)].

Lymphopenia 2 <1 Obtain serum aminotransferase, alkaline phosphatase (ALP), and total bilirubin levels prior to treatment with VUMERITY and during Gastrointestinal treatment, as clinically indicated. Discontinue VUMERITY if clinically Dimethyl fumarate caused GI events (e.g., nausea, vomiting, diarrhea, significant liver injury induced by VUMERITY is suspected. abdominal pain, and dyspepsia). The incidence of GI events was higher early in the course of treatment (primarily in month 1) and 5.6 Flushing VUMERITY may cause flushing (e.g., warmth, redness, itching, and/ usually decreased over time in patients treated with dimethyl fumarate or burning sensation). In clinical trials of dimethyl fumarate (which has compared with placebo. Four percent (4%) of patients treated with the same active metabolite as VUMERITY), 40% of dimethyl fumarate- dimethyl fumarate and less than 1% of placebo patients discontinued treated patients experienced flushing. Flushing symptoms generally due to gastrointestinal events. The incidence of serious GI events was began soon after initiating dimethyl fumarate and usually improved 1% in patients treated with dimethyl fumarate. or resolved over time. In the majority of patients who experienced Hepatic Transaminases flushing, it was mild or moderate in severity. Three percent (3%) of An increased incidence of elevations of hepatic transaminases in patients discontinued dimethyl fumarate for flushing and <1% had patients treated with dimethyl fumarate was seen primarily during serious flushing symptoms that were not life-threatening but led the first six months of treatment, and most patients with elevations to hospitalization. had levels <3 times the upper limit of normal (ULN) during controlled Administration of VUMERITY with food may reduce the incidence of trials. Elevations of alanine aminotransferase and aspartate flushing [see Dosage and Administration (2.3)]. Studies with dimethyl aminotransferase to ≥3 times the ULN occurred in a small number of fumarate show that administration of non-enteric coated aspirin (up to patients treated with both dimethyl fumarate and placebo and were a dose of 325 mg) 30 minutes prior to dosing may reduce the incidence balanced between groups. There were no elevations in transaminases or severity of flushing [see Clinical Pharmacology (12.3)]. ≥3 times the ULN with concomitant elevations in total bilirubin >2 times the ULN. Discontinuations due to elevated hepatic transaminases 6. ADVERSE REACTIONS The following important adverse reactions are described elsewhere were <1% and were similar in patients treated with dimethyl fumarate or placebo. in labeling: • Anaphylaxis and Angioedema [see Warnings and Precautions (5.1)] Eosinophilia • Progressive Multifocal Leukoencephalopathy [see Warnings and A transient increase in mean eosinophil counts was seen during the Precautions Section (5.2)] first 2 months of therapy.

• Herpes Zoster and Other Serious Opportunistic Infections [see Adverse Reactions in Clinical Studies with VUMERITY Warnings and Precautions (5.3)] In clinical studies assessing safety in patients with RRMS, approximately • Lymphopenia [see Warnings and Precautions (5.4)] 700 patients were treated with VUMERITY and approximately • Liver Injury [see Warnings and Precautions (5.5)] 490 patients received more than 1 year of treatment with VUMERITY. • Flushing [see Warnings and Precautions (5.6)] The adverse reaction profile of VUMERITY was consistent 6.1 Clinical Trials Experience with the experience in the placebo-controlled clinical trials with Because clinical trials are conducted under widely varying conditions, dimethyl fumarate. adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may 6.2 Postmarketing Experience The following adverse reaction has been identified during post approval not reflect the rates observed in clinical practice.

use of dimethyl fumarate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Liver function abnormalities (elevations in transaminases ≥3 times ULN with concomitant elevations in total bilirubin >2 times ULN) have been reported following dimethyl fumarate administration in post marketing experience [see Warnings and Precautions (5.5)].

Herpes zoster infection and other serious opportunistic infections have been reported with dimethyl fumarate administration in postmarketing experience [See Warnings and Precautions (5.3)].

8. USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate data on the developmental risk associated with the use of VUMERITY® (diroximel fumarate) or dimethyl fumarate (which has the same active metabolite as VUMERITY) in pregnant women. In animal studies, administration of diroximel fumarate during pregnancy or throughout pregnancy and lactation resulted in adverse effects on embryofetal and offspring development (increased incidences of skeletal abnormalities, increased mortality, decreased body weights, neurobehavioral impairment) at clinically relevant drug exposures [see Data].

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.

17. PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).

Dosage and Administration Inform patients that they will be provided a starter dose bottle: one capsule twice a day for the first 7 days and then two capsules twice a day thereafter. Advise patients to take VUMERITY as instructed.

Inform patients to swallow VUMERITY capsules whole and intact.

Inform patients to not crush, chew, or sprinkle capsule contents on food. Inform patients that they should avoid a high-fat, high-calorie meal/snack at the time they take VUMERITY. If taken with food, the meal/snack should contain no more than 700 calories and no more than 30 g fat. Advise patients to avoid co-administration of VUMERITY with alcohol [see Dosage and Administration (2.2)].

Anaphylaxis and Angioedema Advise patients to discontinue VUMERITY and seek medical care if they develop signs and symptoms of anaphylaxis or angioedema [see Warnings and Precautions (5.1)].

Progressive Multifocal Leukoencephalopathy Inform patients that progressive multifocal leukoencephalopathy (PML) has occured in patients who received dimethyl fumarate, and therefore may occur with VUMERITY. Inform the patient that PML is characterized by a progression of deficits and usually leads to death or severe disability over weeks or months. Inform the patient of the importance of contacting their healthcare provider if they develop any symptoms suggestive of PML. Inform the patient that typical symptoms Data associated with PML are diverse, progress over days to weeks, and Animal Data include progressive weakness on one side of the body or clumsiness Oral administration of diroximel fumarate (0, 40, 100, or 400 mg/kg/ of limbs, disturbance of vision, and changes in thinking, memory, day) to pregnant rats throughout organogenesis resulted in a decrease and orientation leading to confusion and personality changes [see in fetal body weight and an increase in fetal skeletal variations at the Warnings and Precautions (5.2)]. highest dose tested, which was associated with maternal toxicity.

Plasma exposures (AUC) for MMF and HES (the major circulating drug- Herpes Zoster and Other Serious Opportunistic Infections related compound in humans) at the no-effect dose (100 mg/kg/day) Inform patients that herpes zoster and other serious opportunistic for adverse effects on embryofetal development were approximately infections have occurred in patients who received dimethyl fumarate 2 times those in humans at the recommended human dose (RHD) of and therefore may occur with VUMERITY. Instruct the patient of the importance of contacting their doctor if they develop any signs or 924 mg/day.

Oral administration of diroximel fumarate (0, 50, 150, or 350 mg/kg/ symptoms associated with herpes zoster or other serious opportunistic day) to pregnant rabbits throughout organogenesis resulted in an infections [see Warnings and Precautions (5.3)]. increase in fetal skeletal malformations at the mid and high doses and Lymphocyte Counts reduced fetal body weight and increases in embryofetal death and Inform patients that VUMERITY may decrease lymphocyte counts. A fetal skeletal variations at the highest dose tested. The high dose was blood test should be obtained before they start therapy. Blood tests are associated with maternal toxicity. Plasma exposures (AUC) for MMF also recommended after 6 months of treatment, every 6 to 12 months and HES at the no-effect dose (50 mg/kg/day) for adverse effects on thereafter, and as clinically indicated [see Warnings and Precautions embryofetal development were similar to (MMF) or less than (HES) (5.4) and Adverse Reactions (6.1)]. those in humans at the RHD. Oral administration of diroximel fumarate (0, 40, 100, or 400 mg/kg/day) Liver Injury to rats throughout gestation and lactation resulted in reduced weight, Inform patients that VUMERITY may cause liver injury. Instruct which persisted into adulthood, and adverse effects on neurobehavioral patients treated with VUMERITY to report promptly to their healthcare function in offspring at the highest dose tested. Plasma exposures provider any symptoms that may indicate liver injury, including fatigue, (AUC) for MMF and HES at the no-effect dose for adverse effects on anorexia, right upper abdominal discomfort, dark urine, or jaundice. A postnatal development (100 mg/kg/day) were approximately 3 times blood test should be obtained before patients start therapy and during treatment, as clinically indicated [see Warnings and Precautions (5.5)].

(MMF) or similar to (HES) those in humans at the RHD. 8.2 Lactation Risk Summary There are no data on the presence of diroximel fumarate or metabolites (MMF, HES) in human milk. The effects on the breastfed infant and on milk production are unknown.

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VUMERITY and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition.

8.4 Pediatric Use Safety and effectiveness established.

in

pediatric

patients

have

not

Flushing and Gastrointestinal (GI) Reactions Flushing and GI reactions (abdominal pain, diarrhea, and nausea) are the most common reactions, especially at the initiation of therapy, and may decrease over time. Advise patients to contact their healthcare provider if they experience persistent and/or severe flushing or GI reactions. Advise patients experiencing flushing that taking VUMERITY with food (avoid high-fat, high-calorie meal or snack) or taking a nonenteric coated aspirin prior to taking VUMERITY may help [see Dosage and Administration (2.2) and Adverse Reactions (6.1)].

Pregnancy been Instruct patients that if they are pregnant or plan to become pregnant while taking VUMERITY they should inform their healthcare provider [see Use in Specific Populations (8.1)].

8.5 Geriatric Use Clinical studies of dimethyl fumarate and VUMERITY did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients.

8.6 Renal Impairment No dosage adjustment is necessary in patients with mild renal impairment. Because of an increase in the exposure of a major metabolite [2-hydroxyethyl succinimide (HES)], use of VUMERITY is not recommended in patients with moderate or severe renal impairment [see Clinical Pharmacology (12.3)].

Manufactured for: Biogen Inc. Cambridge, MA 02142 VUMERITY is a registered trademark of Biogen. © Biogen 2021

AANnews · April 2022

April Highlights The Mission of the AAN is to promote the highest quality patient-centered neurologic care and enhance member career satisfaction.

The Vision of the AAN is to be indispensable to our members.

Contact Information American Academy of Neurology 201 Chicago Avenue Minneapolis, MN 55415 Phone: (800) 879-1960 (toll free) (612) 928-6000 (international) Email:

memberservices@aan.com

Website: AAN.com For advertising rates, contact: Michael J. O’Brien II Account/Relationship Manager Wolters Kluwer Phone: (978) 578-4514 Email:

Michael.Obrien @wolterskluwer.com

11

Tips For Improving Payer Relations

Working with payers can be cumbersome but these relationships are some of the most beneficial to maintain for a practice or administrative department. The AAN has developed some tips for working with your payers to support your practice needs.

14

New Stroke Prevention Advisory Published

19

Congratulations New Fellows of the American Academy of Neurology!

The AAN published “Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory” online on March 21, 2022, and the March 22 print issue of Neurology ®. This practice advisory reviews and explains the data supporting recommendations for medical management for reducing the risk of recurrent stroke or death in patients with symptomatic intracranial atherosclerotic arterial stenosis (s-ICAS).

The AAN congratulates the members who were named prestigious Fellows of the American Academy of Neurology (FAAN) between November 2021 and February 2022.

AAN Chief Executive Officer: Mary E. Post, MBA, CAE

Editor-in-Chief: Melissa W. Ko, MD, FAAN, CPE Managing Editor: Angela M. Babb, MS, CAE, APR Editor: Tim Streeter Writers: Ryan Knoke and Sarah Parsons Designer: Siu Lee Email: aannews@aan.com AANnews® is published monthly by the American Academy of Neurology for its 38,000 members worldwide.

Access this magazine and other AAN publications online at AAN.com.

The American Academy of Neurology ’s registered trademarks and service marks are registered in the United States and various other countries around the world.

“American Brain Foundation” is a registered service mark of the American Brain Foundation and is registered in the United States.

The inclusion of advertisements and/or promotions of Sponsors and other Internet sites or resources that offer content, goods, or services on the Website does not imply endorsement of the advertised/promoted products or services by AAN.

News Briefs Find Your Next Job at AAN Neurology Virtual Career Fair April 25–26 Held in conjunction with the upcoming Virtual Annual Meeting, this Career Fair will feature 40 employers with a variety of opportunities nationwide offering private, same-day interviews. Search the jobs, apply when interested, and interview when convenient. Offered from 12:00 p.m. to 3:00 p.m. ET on April 25 and 26, this event is free for job seekers and no pre-registration is required. Your privacy is ensured— no one can see what jobs you apply for or which employers you interview with.

Contact careers@aan.com for more information.

AAN in the News A Neurology ® study showing that people with Parkinson’s disease who eat a diet rich in flavonoids may live longer was mentioned in the Chicago Tribune, U.S. News & World Report, and other outlets. Another Neurology study that shows no link between strep throat and tics was covered by Health Day and Drugs.com. And a Neurology study linking formaldehyde exposure on the job to cognitive problems later was picked up by The Washington Post and reprinted by The Boston Globe. 

PRESIDENT'S COLUMN For the Love of Science While COVID struck all of us professionally in indelible ways, arguably those who are scientists have endured some of the most devastating career setbacks of all. Among the American Academy of Neurology’s 641 researcher members, there were those whose trials were terminated due to inability to maintain cell lines or care for animal subjects, deployment to clinical duties, or restricted use of research facilities. The pandemic also dissuaded clinical trial enrollment or discouraged existing enrollees’ continued participation. Personnel losses from faculty furloughs, departures of clinical research coordinators, and other key laboratory employees stressed an already precarious infrastructure. The pressures were so great, in some cases, that a wave of researchers left academics entirely to go to industry or private practice. Along with the Great Resignation came unprecedented supply chain shortages which further crippled research at the cost of additional expense and time.

Avitzur

But throughout it all, many persevered, and despite the obstacles, some have succeeded in bringing their exciting―and all-the-more precious―science to our Annual Meeting in Seattle this month. Here are the stories of three scientists who prevailed.

The closure of several research facilities in the Philippines during lockdowns and establishment of social distancing limited face-to-face interactions of researchers, a challenge Adrian Espiritu, MD, MSc (cand.), currently a multiple sclerosis fellow at the University of Toronto, and his colleagues Espiritu were ultimately able to address by videoteleconferencing. The pandemic also added to a financial burden on research project expenses, on top of the preexisting problem of inadequate research funding in the Philippines, which they were able to overcome thanks to generous research grants from the Philippine Neurological Association and the Philippine General Hospital. Furthermore, the pandemic imposed intrinsic changes to institutional logistic procedures, research processes including protocol development, ethical review applications, participant recruitment, data collection and analysis, and manuscript writing, all of which took considerably longer to accomplish than usual. Personally, Dr. Espiritu had to shuffle several important tasks such as preparing for the specialty board examinations and completing coursework for his master’s degree, all while juggling clinical responsibilities.

Despite those obstacles, Dr. Espiritu conducted a nationwide, multicenter, respective cohort study with his colleagues that incorporated people who had COVID-19 admitted to 37 hospitals across several regions of the Philippines. The study found that new-onset neurologic symptoms independently increased the risk of mortality, respiratory failure, and ICU admissions among COVID-19 patients. His work is being recognized in Seattle with the bestowal of the esteemed Bruce S. Schoenberg International Award in Neuroepidemiology. The pandemic made existing disparities in resources needed to accomplish research wider and more apparent, especially in developing countries like the Philippines, said Dr. Espiritu, who plans to continue his work by setting up an MS clinic and research center when he returns to the Philippines.

8

AANnews • April 2022

Another of those scientists is Shibani Mukerji, MD, PhD, assistant professor of neurology at Harvard, who will be exhibiting her abstract demonstrating the correlation of blood-brain disruption with proinflammatory cytokines and chemokines in patients with COVID-19.

Mukerji Although her MGH lab had existing institutional review board protocols and deep relationships with the microbiology and infectious diseases department members which helped buffer her work initially, she suffered from isolation and struggled to return her lab’s work to HIV, her research focus, in 2021. Further compounding her dilemma was the lack of childcare for her elementary school-aged daughter during the pandemic. This compounded her exhaustion as it meant she often needed to work weekends, late nights, and early mornings to stay afloat. Lack of faceto-face communication with colleagues was particularly difficult as she wrote her first R01 grant and tried to set up an independent lab. She partly attributes her ultimate success to a professional coach—hired from funds set aside by her institution for well-being—who helped her craft her career agenda, develop action plans, and improve her efficiency.

The pandemic also presented multiple logistical challenges to UCSF pediatric neurologist and researcher Alex Fay, MD, PhD, when families of patients were unable or unwilling to risk travel with their children.

Dr. Fay—who divides his time between caring for people with neuromuscular Fay disorders and cerebral palsy, performing clinical trials, and laboratory collaborations focused on neurogenetics and preclinical development of therapeutics— had brought children to UCSF from four continents before the pandemic to take part in a trial of a novel therapeutic, RT001, in treating infantile neuroaxonal dystrophy (a devastating degenerative disorder that results in psychomotor regression and death, usually by age 10). By deploying telehealth, training local physicians to perform clinical assessments, and reviewing those visits live or recorded, the study was able to be completed

and the abstract was accepted by the AAN to be exhibited at the Annual Meeting.

Dr. Mukerji, reflecting on the impact of COVID-19 on young researchers like herself, said, “Professionally, I anticipate the full brunt of the burdens faced by myself, my colleagues, and other junior faculty as part of the pandemic will only be understood in hindsight. I hope that as the field of neurology tries to return to a semblance of normalcy, it will recognize career choices made or not made by junior faculty.”

This year’s Presidential Lecture, “Post-COVID Challenges to Scientific Research,” held on Sunday, April 3, will delve more deeply into the threat to scientific research created by the COVID-19 pandemic. Nina F. Schor, MD, PhD, FAAN; Merit E. Cudkowicz, MD, MSC; and Brenda Banwell, MD, FAAN, will present the challenges and offer potential solutions to address them.

“It shouldn't matter to see each other in person―scientists are used to communicating asynchronously, even over years, with each other’s data and writing. Terry Cascino and Ralph Sacco and Jim Stevens taught me, however, that there is nothing more rewarding as a product of research than a warm smile, the alert look of delight in a colleague’s eyes when you tell them something surprising, and even the lively tone of challenge and debate that neurologists are so much teased for by other specialties. I’m looking forward to enjoying all of these right brain benefits when I go to Seattle― because, after all, the right brain is the dominant hemisphere for this scientist.” ― A.M. Barrett, MD, FAAN

I am both thankful and delighted that so much new and thought-provoking neuroscience will be shared—in person, at last!—in Seattle. Below, I am pleased to share some comments from our neuroscience members about what they are looking forward to. 

Orly Avitzur, MD, MBA, FAAN President, AAN oavitzur@aan.com @OrlyA on Twitter

“The Great Neuro Reunion is the finest forum for sharing the endeavor of systematic observations and experiments.

It highlights the brilliant minds of our most treasured neurologists and neuroscientists.” ―Marcelo Matiello, MD

“It is invigorating to know that soon the large neuroscience family will reconnect again at the 2022 AAN Annual Meeting in Seattle. With the pandemic, the quote from Dickens ‘The pain of parting is nothing to the joy of meeting again’ certainly took a different dimension.” ―Fernando Testai, MD, PhD, FAAN

“It means a hoped-for return to normalcy, with a free and open exchange of ideas with people in the same room at the same time.” ―John Corboy, MD, FAAN

AANnews • April 2022

9

PRACTICE Axon Registry Integration Deadline Soon One of the many benefits of the Axon Registry® is providing AAN US members the opportunity for submitting Merit-based Incentive Payment System (MIPS) reporting to the Centers for Medicare & Medicaid Services. Each year, more than half of Axon Registry practices use the free MIPS reporting feature as a solution. Currently, there are 35 quality measures that Axon Registry participants can choose to work on that will meet CMS MIPS quality component reporting requirements. The Axon Registry has exclusive neurology-specific measures not available via other CMS MIPS quality component reporting methods.

These measures are available for patients with headache, epilepsy, polyneuropathy, multiple sclerosis, Parkinson’s disease, back pain, and more. Visit AAN.com/practice/axon-registry-qualitymeasures for the comprehensive list of Axon Registry measures.

If you are not currently an active participant in the Axon Registry, you will need to act soon to take advantage of this free member benefit for MIPS 2022 submission. To ensure your practice is ready for MIPS submission for the 2022 year, June

30 is the deadline to join the Axon Registry. Joining the Axon Registry after June 30 does not guarantee that your practice will be able to submit for MIPS through the Axon Registry.

For current participants, reach out to your account manager at Verana Health to discuss which quality measures your practice wants to report in 2022.

For more information on how to join the Axon Registry, visit AAN.com/Axon or contact registry@aan.com. For more information on CMS Quality Payment Program (QPP) MIPS program requirements, please visit qpp.cms.gov/mips/ quality-requirements. The AAN has additional resources to help understand CMS’ QPP requirements available at AAN.com/QPP. 

Tips For Improving Payer Relations Working with payers can be cumbersome but these relationships are some of the most beneficial to maintain for a practice or administrative department. The AAN has developed some tips for working with your payers to support your practice needs.

The most important thing in building relationships is identifying the right contact and knowing who the regional and national payers are in your service area. The payer representative relationship is the next key in working with payers. It is recommended to keep communication clear, open, and transparent with payers to develop long-term relationships.

to the office reduces readmission, this can help with your negotiations. Using generic drugs or breaking up combination drugs can increase cost effectiveness and further demonstrate to your payers you are interested in a working relationship.

“For payer negotiations, as in life, the key is a good relationship,” said Jose M. Rocha, MHL, administrator at FirstChoice Neurology in Medley, FL, and member of the AAN Coding and Payment Policy Subcommittee. “So, if you don’t know or work routinely with your payer representative that is what you should negotiate first—that relationship.”

Please contact us at practice@aan.com for additional help working with payers and all your practice needs. 

When reviewing and negotiating your payer contracts, you should know what quality metrics are tracked by the payer as well as any quality programs you can participate in. It is important to note hospital services are a health plan’s biggest cost followed by pharmaceutical cost. Here are a few things you can do to help reduce these costs and help health plans.

1. Reduce re-hospitalization 2. Reduce cost of drugs 3. Properly use ICD-10 non-specific codes vs. specific codes

oving r p m I r o Tips F elations ion Payer R pitalizat

If you can demonstrate how you can keep patients out of the hospital, or how transitioning patients from the hospital

os uce re-h 1 Red ugs ost of dr c e c u d 2 Re -10 use ICD es vs y l r e p o d r 3 P on-specific co n s e d o c specific

Rocha

PRACTICE New Brain & Life Podcast Debuts The AAN’s new Brain & Life podcast is an entertaining weekly podcast exploring the intersection of brain health and neurologic disease. Join neurologist co-hosts Daniel J. Correa, MD, FAAN, and Audrey R. Nath, MD, PhD, in lively conversations with neurology experts, celebrity advocates, and people whose lives are affected by brain conditions.

The podcast will educate and inspire people to maintain a healthy brain and live well with neurologic conditions.

“This is an exciting tool to amplify the community’s voice, support public health education, and reduce stigma for the one in six persons with neurologic conditions,” said Correa. “For our colleagues, we hope the episodes are not just an enjoyable insight into patient perspectives, but also a resource to your patients and their families. We welcome your input on topics, guests, and medical experts to highlight in our schedule. Join us each week on your favorite podcast platform.”

"It's so exciting to be able to reach out and bring stories of living with neurologic conditions from real people,” Nath

Correa

Nath

said. “We get to speak with patients and caregivers, both well known to the public as well as family members in the community. It is an honor to help our patients tell their stories and include upto-date information from experts as well."

New episodes of the Brain & Life podcast will come out weekly on Thursdays.

Listen and subscribe wherever you get your podcasts!

Follow and subscribe wherever you get your podcasts! For more information, visit BrainandLife.org/podcast. 

Actor and Activist Take Action for Health Care Reform The April/May issue of Brain & Life® tells how actor Bradley Whitford and activist Ady Barkan joined forces to reform health care, an issue made more urgent by Barkan’s diagnosis of amyotrophic lateral sclerosis (ALS). The feature story chronicles Barkan’s journey with ALS, his activism, his friendship with Whitford, and how the two were involved in a 2021 documentary called Not Going Quietly that follows Barkan on a nationwide road trip in advance of the 2018 midterm elections advocating for health care reform before politicians and policymakers.

Advocacy can take many forms from speaking up about specific needs and educating others about neurologic conditions to influencing policy that will affect a lot of people. This issue offers expert advice on how to become the kind of advocate that changes policy in meaningful ways.

Viruses mutate, as evidenced by the many variants of COVID-19.

Another feature story explains how and why this happens, how mutations can be forestalled, and how they affect vaccines, boosters, and future pandemics.

Brain & Life magazine is free for AAN members in the United States to distribute to patients, who also can subscribe for free. If you would like to adjust the number of copies you receive for your patients or update your clinic address, email BeGreen@WasteFreeMail.com. All members have online access to the magazine articles and additional resources at BrainandLife.org. Please share the website with your patients! 

12

AANnews • April 2022

Stay Informed with Latest Neurology: Clinical Practice The new issue of Neurology ® Clinical Practice offers an informative collection of research and commentary articles, including “Cerebrospinal Fluid Biomarkers Predict Gait Outcomes in Idiopathic Normal Pressure Hydrocephalus,” by Abhay Moghekar, MD, et al.; “Sources of Cannabis Information and Medical Guidance for Neurological Use: NARCOMS Survey of People Living with Multiple Sclerosis,” by Amber Salter, PhD, et al.; “Association of Performance on the Financial Capacity Instrument-Short Form with Brain Amyloid Load and Cortical Thickness in Older Adults,” by Maria Vassilaki, MD, MPH, PhD, et al.; “Fast Neuro: A Care Model to Expedite Access to Neurology Clinic,” by Melissa Reider-Demer, DNP, MSN, CNP, et al.; and “Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease,”

by Andrew J. McGarry, MD, et al.

Volume 12, Num

ber 2, April 2022

Neurology.o

rg/CP

A peer-reviewed

clinical neurolog

y journal for the

practicing neur

ologist

RESEARCH

Sources of Cannab is Information and Guidance for Neu Medical rologic Use: NA RCOMS Sur vey of People Living With Multiple Scle rosis

RESEARCH

Published continuously online and in print six times a year, Neurology: Clinical Practice is free to AAN members via the website (and available in print for US members only) who have a current subscription to Neurology. Visit Neurology.org/cp for more information. 

Fast Neuro: A Car e Model to Expedit Neurology Clin e Access to ic COMMENTARY

Improving Access to Tertiar y Movem Subspecialty Car ent Disorders e: A Team Model Born From the COVID-19 Crisis FIVE NEW THIN

GS

Essential Tremo r: Five

New Things

MEM: 22 Member Dues Renewal Ad—Half Page Horizontal> AN Placed in AANnews 8.25 x 5.25 +0.125 bleed, 4C

Community Education

Professional Growth

Practice Management

Advocacy

Wellness Research

WHAT YOU NEED

WHEN YOU NEED IT Only AAN membership offers access to the highest quality resources— when you need them—from the world’s largest and most trusted community of neurology professionals.

Join or renew today.

AAN.com/Membership

GUIDELINES AAN Publishes Evidence-in-Focus Article on Aducanumab The AAN published an Evidence-in-Focus article―a synthesis of published evidence currently available on the drug aducanumab― online on February 23, 2022, and in the April 12 print issue of Neurology®. It was developed using a process designed by the AAN Guidelines Subcommittee to quickly provide the highest quality data on this new drug along with discussions for shared decision-making.

Aducanumab is the first drug approved by the Food and Drug Administration to treat pathological changes associated with Alzheimer disease (AD) rather than manage symptoms of the disease. The drug is approved to treat people with early symptomatic AD, including patients with mild cognitive impairment and mild dementia. Aducanumab targets a substance called amyloid-β that builds up in the brains of patients with AD and forms amyloid “plaques.” It is not known for sure, but evidence points to amyloid-β plaques playing a role in the development of AD-related cognitive impairment.

Convincing evidence for a meaningful clinical benefit associated with aducanumab use is lacking. Studies consistently demonstrate that aducanumab promotes removal of brain amyloid deposits. Whether aducanumab affects cognition or daily function is unclear, with studies showing mixed

results of uncertain relevance over the study’s duration. Additionally, amyloidrelated brain imaging abnormalities (including either brain swelling or bleeding) occurred in about 40 percent of people treated with aducanumab, although this resolved in most instances.

Aducanumab reduced cerebral amyloid in patients with symptomatic Alzheimer diseases. There is ambiguous evidence regarding clinical efficacy of aducanumab in patients with MCI or early-stage dementia due to Alzheimer disease who were enrolled in clinical trials: one Class II, phase III study demonstrated some slowing of rates of cognitive decline, while another Class II, phase III study failed to demonstrate such efficacy. In the study that showed a difference with aducanumab treatment, it was unclear if the difference was meaningful. Brain edema or hemorrhage was detected in about 40

percent of patients. Adverse events, such as those listed above led to drug discontinuation in nine percent (vs four percent in the placebo group). In most patients, brain edema and hemorrhage resolve with temporary or permanent discontinuation of the drug, without permanent or severe disability. Rare patients with serious adverse events and protracted complications (even death) were recognized in the clinical trials.

These findings emphasize the need for close monitoring, including longitudinal brain imaging of asymptomatic patients and rapid assessment/imaging of symptomatic patients.

If considering prescribing aducanumab, clinicians should provide information about eligibility, balance of risks and benefits, and other treatment considerations for patients and their families.

For more information, email guidelines@ aan.com or visit AAN.com/aducanumab. 

New Stroke Prevention Advisory Published The AAN published “Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory” online on March 21, 2022, and the March 22 print issue of Neurology®. This practice advisory reviews and explains the data supporting recommendations for medical management for reducing the risk of recurrent stroke or death in patients with symptomatic intracranial atherosclerotic arterial stenosis (s-ICAS).

The advisory says antithrombotics, dyslipidemic agents, and lifestyle modification can all be effective management options. Stenting should not be recommended as the initial treatment for s-ICAS. Additional research is underway to determine the effectiveness of other management approaches, including other antithrombotics and endovascular/surgical techniques.

The practice advisory recommends: Clinicians should recommend aspirin 325 mg/d for longterm prevention of stroke and death in patients with s-ICAS and if the stenosis is severe (70%–99%), add clopidogrel 75mg/d to aspirin for up to 90 days.

Clinicians should recommend high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol (LDL-C) <70 mg/dL, a long-term blood pressure target of <140/90 mm Hg, at least moderate physical activity, and treatment of other modifiable vascular risk factors for s-ICAS patients.

14

AANnews • April 2022

Clinicians should not recommend percutaneous transluminal angioplasty and stenting (PTAS) or direct bypass for stroke prevention in patients with moderate (50%–69%) s-ICAS or as the initial treatment for stroke prevention in patients with severe (70%–99%) s-ICAS. Clinicians should not routinely recommend angioplasty alone or indirect bypass for stroke prevention in patients with s-ICAS outside of clinical trials.

For more information, email guidelines@aan.com. 

ADVOCACY

Capitol Hill Report Capitol Hill Report presents regular updates on legislative and regulatory actions and how the Academy ensures that the voice of neurology is heard on Capitol Hill. It is emailed to US members twice monthly and is posted at AAN.com/view/HillReport. Below are some recent highlights.

Latest Advocacy News

Issue in Focus

On February 23, a federal court struck down a key provision of recently finalized regulations implementing the federal law banning surprise billing. The provision had instructed mediators tasked with resolving payment disputes between payers and providers to use a presumption in favor of the “qualifying payment amount” when determining the payment owed to an out-of-network provider.

The AAN previously submitted comments raising concerns that this presumption is biased against providers and urged the administration to reconsider this decision.

Each year, the AAN asks members to rank their top policy priorities to help us determine our areas of focus for the year ahead. In the online survey issued last November and December, 594 respondents ranked the top three issues they felt should be AAN policy priorities in 2022 as administrative burden associated with prior authorization (53 percent), drug costs (43 percent), and Medicare reimbursement (41 percent). Addressing workforce shortages for both neurologists and support staff was also identified as a rising topic of concern for members.

Seventy-one percent of respondents said financial barriers to patient care was a top issue for their patients.

The AAN has launched a new campaign to urge Congress to increase funding for the VA Neurology Centers of Excellence that focus on epilepsy, headache, multiple sclerosis, and Parkinson’s disease for fiscal year 2023. This effort builds off the success the AAN had during fiscal year 2022 in supporting these centers.

High drug costs lead to use management techniques like prior authorization. Until high drug costs are addressed, we will continue to see the use of burdensome policies to restrict access. The AAN remains committed to strong support for policies to address both prior authorization and high drug costs.

The Academy continues to strongly support legislative and regulatory policies that value evaluation and management services. We continue to focus on efforts to protect the gains made last year and will work to head off challenges in the year ahead. 

AANnews • April 2022

15

EDUCATION Continuum Spotlights Epilepsy Epilepsy is examined in the current issue of Continuum: Lifelong Learning in Neurology®, and Guest Editor Nathalie Jetté, MD, MSc, FRCPC, CSCN(EEG), FAAN, FAES, FANA, highlighted some of the new information available in this issue.

“This issue features the latest epilepsy-related advances and topics including the up-to-date treatment of status epilepticus, imaging modalities, pregnancy outcome data, management of psychiatric comorbidity, and clinical features of genetic epilepsy syndromes. Readers will also learn about scoring systems to aid in the identification of autoimmune encephalitis and autoimmune epilepsy.”

Content for this issue includes:

Jetté

Evaluation of First Seizure and Newly Diagnosed Epilepsy / Elaine Wirrell, MD, FRCP(C), FAAN

Update on Antiseizure Medications 2022 / Bassel W. Abou-Khalil, MD, FAAN

EEG Essentials / William O. Tatum IV, DO, FAAN, FACNS, FAES

Surgical Treatments for Epilepsy / George W. Culler IV, MD; Barbara C. Jobst, Dr Med, PhD, FAAN

Neuroimaging of Epilepsy / Samuel Lapalme-Remis, MDCM, MA, FRCPC; Dang K. Nguyen, MD, PhD, FRCPC Genetic Epilepsy Syndromes / Kenneth A. Myers, MD, PhD, FRCPC, CSCN(EEG) Autoimmune-associated Seizures / Lisa Gillinder, MBBS, FRACP; Jeffrey Britton, MD, FAAN Women’s Issues in Epilepsy / Esther Bui, MD, FRCP(C) Seizures and Epilepsy in Childhood / Maria Gogou, MD, PhD; Judith Helen Cross, MBChB, PhD Neuropsychiatric and Cognitive Comorbidities in Epilepsy / Marco Mula, MD, PhD, FRCP, FEAN; Honor Coleman, MPsych, PhD; Sarah J. Wilson, PhD, FAHMS, FASSA Approach to the Medical Treatment of Epilepsy / Francesco Brigo, MD; Anthony Marson, MBChB, MD, FRCP

Management of Status Epilepticus, Refractory Status Epilepticus, and Super-refractory Status Epilepticus / Eugen Trinka, MD, MSc, FRCP; Markus Leitinger, MD, MSc This issue includes a postreading self-assessment and test with the opportunity to earn up to 20 AMA PRA Category 1 Credits™ toward Self-assessment CME. Until June 30, 2022, subscriptions and renewals to Continuum® are 15-percent off the already low AAN member rate. AAN members pay just $339 per year for a subscription to Continuum and Continuum® Audio. Subscribe now by contacting Wolters Kluwer at (800) 361-0633 or (301) 223-2300 (international) or visit shop.lww.com/continuum and enter code WMQ074AA at checkout to receive the discounted price. AAN junior member who are transitioning to neurologist memberships are eligible to receive a 60-percent discount on the already low member rate for the Continuum and Continuum Audio subscription. 

2022 UCNS Continuous Certification Reading Lists Available The United Council for Neurologic Subspecialties’ 2022 continuous certification (C-cert) reading lists are now available for Autonomic Disorders, Behavioral Neurology & Neuropsychiatry, Clinical Neuromuscular Pathology, Headache Medicine, Neurocritical Care, Neuroimaging, and Neuro-oncology.

Reading lists include links to the journal articles submitted by subspecialty peers

and selected by each subspecialty’s certification examination committee based on specific criteria.

C-cert activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty and include completing

the reading lists and taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. UCNS certification is continuous and does not expire when diplomates meet the annual C-cert requirements.

Learn more and access the C-cert reading lists at UCNS.org/ReadingLists. 

Apply by June 1 for Subspecialty Fellowship Program Accreditation Applications for subspecialty fellowship programs seeking United Council for Neurologic Subspecialties (UCNS) accreditation are due by June 1. Accreditation is a measure of training program excellence and UCNS-accredited programs demonstrate that they meet the standards of graduate medical education excellence set by both the UCNS and the subspecialty experts of each of the UCNS-recognized subspecialties. The peer-reviewed accreditation process is overseen by the Accreditation Council, a standing committee reporting to the UCNS Board of Directors. Visit UCNS.org/Accreditation to learn more and to apply. 

16

AANnews • April 2022

Thank You

2O22 Industry Roundtable Members* The American Academy of Neurology and the Industry Roundtable collaborate on opportunities to support neurology and serve patients with neurologic disease.

$50,000 Members

Neurology

$40,000 Members

$25,000 Members

• Harmony Biosciences

• Adamas Pharmaceuticals, Inc.

• Avanir Pharmaceuticals

• Avion Pharmaceuticals

• Horizon Therapeutics

• Alnylam Pharmaceuticals, Inc.

• Axsome Therapeutics

• Idorsia Pharmaceuticals

• Medtronic

• Amneal Specialty, a division of

• Impel NeuroPharma

• Illumina

• Zogenix, Inc.

Amneal Pharmaceuticals LLC

$10,000 Members • UCB, Inc.

*Commitments as of February 9, 2022

MEMBERSHIP

Free AAN Anti-racism Education Program Opens to Members Inclusion is the reason the AAN was founded. To be an organization that is the home for all neurologists. It is what makes us stronger.

To support our goal of being a fully inclusive, deliberately diverse, and anti-racist organization and our core values of Inclusion, Diversity, Equity, Anti-racism, and Social Justice (IDEAS), we are excited to share progress and updates with you.

The AAN has launched a new Anti-racism Education Program. All Academy members are encouraged to enroll in the free program.

Nimish A. Mohile, MD, FAAN, member of the IDEAS Subcommittee, said, “The AAN’s vision is to be indispensable to its members; our mission is to promote the highest quality patient-centered neurologic care and enhance member career satisfaction. We cannot be indispensable, we cannot promote the best care for our patients, or enhance the careers of our members, if we ignore the pervasive inequities that are often barriers in our society. To achieve this vision and mission, we must offer learning opportunities to increase awareness of the toll of racism in society along with building skills for mitigating the impact that historic, deeply rooted, and systemic inequities have on our members, our patients, and the communities we serve.”

The AAN Anti-racism Education Program is an on-demand, self-paced anti-racism core curriculum unique for neurologists. This program is designed to be completed over several months with built-in time for reflection between the four modules covering the following topics: Module 1 Setting the Stage: Reflections on Race, Identity, and Socialization Module 2 The History of Racism in Neurology: Member Experiences with Bias and Racism Module 3 Patient Care Stories: Vignettes in Clinical and Academic Neurology Module 4 Institutional Structures: Racism in Training and Anti-racism Leadership Each module frames the learning objectives in a vignette with breaks to highlight knowledge, skills, and attitudes that should be taken away from the module. There are reflective questions and interactive components throughout the modules and

18

AANnews • April 2022

opportunities for additional learning with links to external resources. These modules are self-paced, and you are invited to return to the material as frequently as needed to support your learning and growth.

Learning Objectives Recognize anti-racism as a professional competency, engage in conversations about race and racism, and practice skills to improve patient care

Mohile

Identify embedded racism and inequities within systems, institutional structures, policies, and their effects on health care outcomes Understand how to apply a racial equity framework to their own clinical practice and in health care systems.

To learn more, visit AAN.com/IDEAS. 

Learn More About the Anti-racism Education Program at the Annual Meeting The new AAN Anti-racism Education Program will be discussed by its creators during the Annual Meeting in Seattle on April 5 from 2:15 p.m. to 3:15 p.m. in the Leadership University Learner Engagement Center. The lead physicians will talk about the new program, why the AAN created it, and the importance of participating. 

Avitzur Hosts Video on Brain Health and Brain Tumors In a new video on brain tumors hosted by President Orly Avitzur, MD, MBA, FAAN, she interviews Katy Peters, MD, PhD, and her patient Rudy Fischmann, a television documentarian who has astrocytoma in brain stem and cerebellum. The three discuss the personal aspects of neurologic care, and the importance of keeping both your brain and body active. Fischmann, through his YouTube channel, uses his skills acquired from his previous career to help himself and others dealing with the many issues that arise from having a serious health diagnosis.

Watch their conversation at YouTube.com/AANchannel. 

Congratulations New Fellows of the American Academy of Neurology!

The AAN congratulates the following members who were named prestigious Fellows of the American Academy of Neurology (FAAN) between November 2021 and February 2022.

Kerstin Bettermann, MD, PhD, FAAN Beau Benjamin Bruce, MD, FAAN Michiko K. Bruno, MD, FAAN James L. Case, MD, FAAN Stanley L. Cohan, MD, PhD, FAAN Carolyn Cronin, MD, PhD, FAAN Neha Dangayach, MD, FAAN Khosro Farhad, MD, FAAN Chung-Yan G. Fong, MD, FRCP, FAAN Rochelle I. Frank, MD, FAAN Norman M. Friedman, MD, FAAN Michele A. Gatheridge, MD, FAAN Christian Gericke, MD, PhD, MPH, MSc, MBA, FAAN Reena Ghode, MD, FAAN Felicia Gliksman, DO, FAAN Gillian L. Gordon-Perue, MD, FAAN Amy K. Guzik, MD, FAAN Vijayakumar Javalkar, MD, FAAN Vita Kesner, MD, PhD, FAAN Matthew Kirschen, MD, PhD, FAAN Sonya Knight, DO, FAAN Tomasz A. Kosierkiewicz, MD, FAAN Sharon Lewis, MD, FAAN Terrence M. Li, MD, FAAN Erin Longbrake, MD, PhD, FAAN Liang Lu, MD, FAAN Achraf Makki, MD, FAAN Moshe Albert Mizrahi, MD, FAAN Rajanandini Muralidharan, MD, FAAN

Umer Najib, MD, FAAN Annette Okai, MD, FAAN Daniel Pastula, MD, MHS, FAAN Gamini Karapitiya Pathirana, MD, MBBS, FAAN Lauren N. Reoma, MD, FAAN Barbara Schauble, MD, PhD, FAAN Courtney Schusse, MD, FAAN Maurizio Severino, MD, PhD, FAAN Sudhir Shah, MD, FAAN Anuradha Singh, MD, FAAN Saurabh R. Sinha, MD, PhD, FAAN Michael Soileau, MD, FAAN Mariana Spitz, MD, FAAN Arturo Tamayo, MD, FAAN Fernando Testai, MD, PhD, FAAN Alejandro Tobon, MD, FAAN Howard J. Tucker, MD, FAAN Nicole Ullrich, MD, FAAN Venka Veerappan, MD, FAAN Mitzi Joi Williams, MD, FAAN Andrew A. Wong, MBBS, PhD, FRACP, FAAN Jessica Zwerling, MD, FAAN 

Interested in Elevating Your Membership Status to FAAN?

Visit AAN.com/FAAN to see if you’re eligible for the FAAN designation— or encourage a qualifying colleague to apply. Applying for FAAN status is free, acknowledges exemplary work and achievements in the neurosciences, the clinical practice of neurology, or academic/ administrative neurology; helps set you apart both within the Academy and throughout your professional career; and offers eligibility to serve on the AAN Board of Directors. 

AANnews • April 2022

19

MEMBERSHIP

Celebrate These 2022 AAN Award Recipients The AAN recognizes the 2022 award recipients and their contributions to the art and science of neurology.

EDUCATION AWARDS Megan E. Esch, MD / Geisinger Commonwealth School of Medicine, Danville, PA

Ram Mohan R. Sankaraneni, MD / Creighton University School of Medicine, Omaha, NE

Gena R. Ghearing, MD / University of Iowa, Iowa City, IA

Fallon Schloemer, DO / Medical College of Wisconsin, Milwaukee, WI

David M. Greer, MD, FAAN / Boston University School of Medicine, Boston, MA

Rachel J. Gottlieb-Smith, MD / University of Michigan, Ann Arbor, MI

Anita Valanju Shelgikar, MD / University of Michigan, Ann Arbor, MI

A.B. Baker Teacher Recognition Award

Raghav Govindarajan, MD, FAAN / HSHS St. Elizabeth's Hospital, O'Fallon, IL

Padmaja Sudhakar, MD / University of Kentucky, Lexington, KY

Zain Guduru, MD / University of Kentucky, Lexington, KY

Bhavesh Trikamji, MD / University of California Riverside, Riverside, CA

Julie E. Hammack, MD, FAAN / Mayo Clinic, Jacksonville, FL

Okeanis Vaou, MD, FAAN / St. Elizabeth's Medical Center, Brighton, MA

Brian James Hanrahan, MD / St. Luke's University Health Network, Bethlehem, PA

Association of Indian Neurologists in America Lifetime Achievement Award

A.B. Baker Award for Lifetime Achievement in Neurologic Education Funded by an endowment created by matching funds from the A.B. Baker Family Trust and Novartis Pharmaceuticals.

Vinita J. Acharya, MD / Pennsylvania State University College of Medicine, Hershey, PA Samiya Fatima Ahmad, MD / Baylor College of Medicine, Houston, TX Dara V. Albert, DO / Nationwide Children's Hospital, Columbus, OH Eric M. Aldrich, MD / Johns Hopkins, Baltimore, MD

Muhammad Rizwan Husain, MD / West Virginia University, Parkersburg, WV

Mohamed Ibrahim Abdul Aleem, MD / ABC Hospital/The Tamilnadu Dr. MGR Medical University/Dhanalakshami Srinivasan Medical College, Trichy/ Chennai, Tamilnadu, India

Sleiman El Jamal, MD / Alpert Brown Medical School/Rhode Island Hospital, Providence, RI

Kapil Arya, MD / University of Arkansas for Medical Sciences, Little Rock, AR

For-Shing Lui, MD, FAAN / California Northstate University, Sacramento, CA

Ahmad Al-Awwad, MD / University of Oklahoma, Oklahoma City, OK

Elizabeth Macri, MD / University of New Mexico, Albuquerque, NM

Amar Bhatt, MD / Rush University Medical Center, Chicago, IL

Scott J. Mendelson, MD, PhD / University of Chicago, Chicago, IL

Nirav R. Bhatt, MD / Emory University School of Medicine, Atlanta, GA

Bindu Menon, MD, MBBS / Apollo Specialty Hospitals, Nellore Andhra Pradesh, India

Rocio Vazquez Do Campo, MD / University of Alabama at Birmingham, Birmingham, AL

Rajeev Motiwala, MD, FAAN / NYU Grossman School of Medicine, New York, NY

Benjamin Robert Claytor, MD / Cleveland Clinic Foundation, Cleveland, OH

Aaron Lane Nelson, MD, FAAN / NYU Langone Health, New York, NY

Consortium of Neurology Residents and Fellows Essay Contest

Kalea Lynn Colletta, DO / Edward Hines Jr. VA Hospital / Loyola University Medical Center, Maywood, IL

Ivan M. Pavkovic, MD / Zucker School of Medicine at Hofstra/Northwell, New York, NY

Maria El-Hallal, MD / Northwell Health System, New Hyde Park, NY

Justin Cornelius, MD / Madurai Medical College, Madurai, Tamilnadu, India

Aparna M. Prabhu, MD / Jefferson Einstein Medical Center, Philadelphia, PA

Saurav Das, MD / University of Kentucky, Lexington, KY

Matthew S. Robbins, MD, FAAN / Weill Cornell Medicine, New York, NY

Mitesh P. Lotia, MD / University of Arkansas, Little Rock, AR

Lawrence M. Samkoff, MD, FAAN / University of Rochester, Rochester, NY

20

Sponsored by the Association of Indian Neurologists in America Fund of the American Brain Foundation.

AANnews • April 2022

Aneesh B. Singhal, MD, FAAN / Massachusetts General Hospital, Boston, MA

Clerkship Director Innovation Award Sponsored by the American Academy of Neurology.

Megan Richie, MD / University of California, San Francisco, San Francisco, CA

Clerkship Director Teaching Award Sponsored by the American Academy of Neurology.

Robert Ian Thompson-Stone, MD, FAAN / University of Rochester, Rochester, NY

Director Mentorship Leadership Program David J. Avila, MD / Geisinger Medical Center, Danville, PA Deborah Bradshaw, MD, FAAN / SUNY Upstate Medical University, Syracuse, NY

Miguel Chuquilin, MD, FAAN, MCh / University of Florida, Gainesville, FL

Laura Kirkpatrick, MD / UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA

Jordan Garris, MD / University of Virginia, Charlottesville, VA

Mahjabeen Ahmed Khan, MBBS / St. Louis University School Of Medicine, St. Louis, MO

Gurmeen Kaur, MBBS / Westchester Medical Center, Valhalla, NY Hani Kushlaf, MD, FAAN / University of Cincinnati, Cincinnati, OH Amy McGregor, MD / UTHSC, Memphis, TN Aaron Nelson, MD, MBS, FAAP, FAAN / NYU Langone Health, New York, NY Setareh Salehi Omran, MD / University of Colorado, Aurora, CO Michael Palm, MD, FAAN / UT Health San Antonio, San Antonio, TX Mehmood Rashid, MD / University of Toledo College of Medicine and Life Sciences, Toledo, OH Angela Shapshak, MD / University of Alabama at Birmingham, Birmingham, AL Jacqueline Stone, MD / Memorial Sloan-Kettering Cancer Center/New YorkPresbyterian Weill Cornell Medical Center, New York, NY Colleen Tomcik, MD / University of Rochester, Rochester, NY

Enhanced Resident Leadership Program Supported in part by Greenwich Biosciences, Inc., ACADIA Pharmaceuticals, Inc., and Neurocrine Biosciences, Inc. Aisha Abdulrazaq, MD / University of Missouri, Columbia, MO

Keng Lam, MD / Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA Steven Lazar, MD / Baylor College of Medicine-Texas Children's Hospital, Houston, TX Eunice Lee, MD / Thomas Jefferson University Hospital, Philadelphia, PA Andrea Lendaris, MD, MS / Montefiore Medical Center, Bronx, NY Jose Ricardo Lopez-Castellanos, MD / University of Arkansas for Medical Sciences, Little Rock, AR Micaela Owens, DO, MHSA / Geisinger Medical Center, Danville, PA Enmanuel Perez, MD, PhD / Department of Neurology, Washington University School of Medicine, St. Louis, MO Mishu Sharma, MD / University of Texas Southwestern Medical Center, Dallas, TX

Andrew Huang, MD / University of Rochester, Strong Memorial Hospital, Rochester, NY Pallavi Juneja, MD / New YorkPresbyterian Hospital/Columbia, New York, NY Laura de Lima Xavier, MD / University of North Carolina Hospitals, Chapel Hill, NC Victoria Reedman, MD / University of Toronto, Toronto, Ontario, Canada Deborah Rose, MD / Duke University Hospital, Durham, NC Sabrina Tavella-Burka, DO / Cleveland Clinic, Cleveland, OH

Neuroscience Course Director Excellence Victor W. Sung, MD / University of Alabama at Birmingham, Birmingham, AL

Residency-Fellowship-Clerkship Program Coordinator Recognition Award Cristina Lender, C-TAGME / University of Connecticut, Farmington, CT Eridiz Diaz / New York University Langone Medical Center, New York, NY

Anna Thamann, MD / University of Louisville Child Neurology, Louisville, KY

Tami Hall / Indiana University School of Medicine, Indianapolis, IN

Frank A. Rubino Award for Excellence in Clinical Neurology Teaching

Janice A. Void / New York PresbyterianWeill Cornell Medicine, New York, NY

Funded by Mayo Clinic Frank A. Rubino, MD Development Fund.

Residency-Fellowship Program Director Recognition Award

Yaacov Anziska, MD / SUNY-Downstate, New York, NY

Marc Alain Babi, MD / University of Florida, Gainesville, FL

Neurologist-in-Training Clinical Ethics Elective

Shilpa Chitnis, MD, PhD, FAAN / UT Southwestern Medical Center, Dallas, TX

Laura Gilbert, DO, MBA / Washington University in St. Louis, St. Louis Children's Hospital, St. Louis, MO

Sponsored by the Ethics, Law, and Humanities Committee, a joint committee of the American Academy of Neurology, the American Neurological Association, and the Child Neurology Society.

Caitlin Hof, MD / University of Iowa Hospitals and Clinics, Iowa City, IA

Danielle Feng, MD / Harbor-UCLA Medical Center, Torrance, CA

Erica A. Schuyler, MD, FAAN / Hartford HealthCare/University of Connecticut, Hartford, CT

Diana Alsbrook, MD / University of Tennessee Health Science Center College of Medicine, Memphis, TN

Sashank Prasad, MD / Brigham and Women's Hospital, Boston, MA

Continued on page 22

›

MEMBERSHIP Celebrate These 2022 AAN Award Recipients continued from page 21 SERVICE AWARDS AAN President's Award

Dr. Viste’s colleagues, friends, and patients.

David A. Evans, MBA / Texas Neurology, Dallas, TX

Nirmal Surya, MD, DNB, FIAN, FRCP / Epilepsy Foundation India, Mumbai, India

Ambassador Award

Mridha Spirit of Neurology Humanitarian Award

Sponsored by the American Brain Foundation.

Susannah Cahalan

Award for Creative Expression of Human Values in Neurology Sponsored by the Ethics, Law, and Humanities Committee, a joint committee of the American Academy of Neurology, the American Neurological Association, and the Child Neurology Society.

James Dolbow, DO / University Hospitals Cleveland Medical Center, Cleveland, OH

Kenneth M. Viste Jr., MD Patient Advocate of the Year Award Sponsored by the American Academy of Neurology and endowed by gifts from

Sponsored by the American Brain Foundation and funded through the philanthropy of Dr. and Mrs. Mridha.

Michael P. Skolka, MD / Mayo Clinic, Rochester, MN

Ted Burns Humanism in Neurology Award Sponsored by the American Brain Foundation.

Barbara S. Giesser, MD, FAAN / Pacific Neuroscience Institute, Santa Monica, CA

Bindu Menon, MD, DM, DNB, PGDCN, FRCP, MNAMS, FICP, FIAN, FWSO / Apollo Specialty Hospitals, Andhra Pradesh, India

Public Leadership in Neurology Award

Bruce Ovbiagele, MD, MSc, MAS, MBA, FAAN / University of California, San Francisco, CA

Seth Rogen and Lauren Miller Rogen

QI Innovation Award Sponsored by the American Academy of Neurology.

Lindsey A. Morgan, MD / Seattle Children's Hospital, Seattle, WA

Sponsored by the American Brain Foundation.

General Neurology Award Sponsored by the American Academy of Neurology.

Sally Harris, MD, FAAN / Sandia Neurology PC, Albuquerque, NM

SCIENTIFIC AWARDS AAN Neuro-infectious Disease Award Sponsored by the American Academy of Neurology.

Payal Patel, MD / University of Washington, Bellevue, WA

Career Development Award

Clinical Research Training Scholarship in ALS Funded by The ALS Association and American Brain Foundation in collaboration with the American Academy of Neurology.

Funded by the American Academy of Neurology.

Sanjana Shellikeri, PhD / University of Pennsylvania, Philadelphia, PA

Meredith Bock, MD / University of California San Francisco, San Francisco, CA

Clinical Research Training Scholarship in FTD

Ronda Lun, MD / The Ottawa Hospital-Civic Campus, Ottawa, Ontario, Canada

Noreen Bukhari-Parlakturk, MD, PhD / Duke University, Durham, NC

Alliance Awards: S. Weir Mitchell

Clinical Research Training Scholarship

Funded by The Holloway Family Fund of The Association for Frontotemporal Degeneration and the Bob Burros Family Memorial Fund of the American Brain Foundation in collaboration with the American Academy of Neurology.

Alliance Awards: Founders Sponsored by the American Academy of Neurology and endowed by the former American Academy of Neurology Alliance.

Sponsored by the American Academy of Neurology and endowed by the former American Academy of Neurology Alliance.

Jean-Pierre Falet, MD, CM / McGill University, Mount Royal, Quebec, Canada

Bruce S. Schoenberg International Award in Neuroepidemiology Sponsored by the American Academy of Neurology and endowed by GlaxoSmithKline, Inc.

22

Adrian Espiritu, MD, MSc (cand.) / University of the Philippines Manila, Manila, Philippines / University of Toronto, Toronto, Ontario, Canada

AANnews • April 2022

Funded by the American Academy of Neurology.

Monica Diaz, MD, MS / University of North Carolina, Chapel Hill, NC Angela Hewitt, MD, PhD / University of Rochester, Child Neurology, Rochester, NY Bipasha Mukherjee-Clavin, MD, PhD / Johns Hopkins University, Baltimore, MD

Indira Garcia Cordero, PhD / University Health Network, Toronto, Ontario, Canada

Clinical Research Training Scholarship in Lewy Body Diseases Funded by The Mary E. Groff Charitable Trust, the Alzheimer's Association, and American Brain Foundation, in collaboration with the American Academy of Neurology.

Zachary Macchi, MD / University of Colorado Denver School of Medicine, Aurora, CO

Natalia Szejko, MD, PhD / University of Calgary, Alberta Children's Hospital, Child Neurology, Calgary, Alberta, Canada

Clinical Research Training Scholarship in Migraine

Clinician Scientist Development Award in Myasthenia Gravis

Funded by Amgen, Inc. and American Brain Foundation in collaboration with the American Academy of Neurology.

Funded by the Myasthenia Gravis Foundation of America and American Brain Foundation in collaboration with the American Academy of Neurology.

Gina Dumkrieger, PhD / Mayo Clinic Arizona, Phoenix, AZ

Clinical Research Training Scholarship in Muscular Dystrophy Funded by the Muscular Dystrophy Association through the American Brain Foundation in collaboration with the American Academy of Neurology.

Samuel Carrell, MD, PhD / University of Pennsylvania, Philadelphia, PA Stefan Nicolau, MD / National Children's, Columbus, OH

Clinical Research Training Scholarship in Neurodisparities Funded by the Hearst Foundation, Eisai, and American Brain Foundation in collaboration with the American Academy of Neurology.

Whitley Aamodt, MD, MPH, MSCE / University of Pennsylvania, Philadelphia, PA

Clinical Research Training Scholarship in Neuromuscular Disease Funded by the Muscle Study Group and American Brain Foundation in collaboration with the American Academy of Neurology.

Tyler Rehbein, MD / University of Rochester, Rochester, NY

Dreifuss-Penry Epilepsy Award

Sponsored by the American Academy of Neurology.

Sponsored by the American Academy of Neurology and endowed by members of the American Academy of Neurology Epilepsy Section; Abbott Laboratories, Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Corporation; GlaxoSmithKline, Inc.; Novartis; OrthoMcNeil Pharmaceutical, Inc.; Pfizer Inc; Shire Pharmaceuticals Group; and UCB Pharma.

Piero Perucca, MD, PhD, FRACP / The University of Melbourne Austin Health, Melbourne, Australia

Harold Wolff-John Graham Award: An Award for Headache/Facial Pain Research Sponsored by the American Academy of Neurology and endowed by Endo Pharmaceuticals.

Caroline Ran, MSc, PhD / Karolinska Institutet, Stockholm, Sweden

Irwin Schatz Award for Autonomic Disorders Sponsored by the American Academy of Neurology and endowed by Lundbeck, Inc.

Funded by the Parkinson's Foundation and American Brain Foundation in collaboration with the American Academy of Neurology.

John Dystel Prize for Multiple Sclerosis Research

Funded by the Tourette Association of America and American Brain Foundation in collaboration with the American Academy of Neurology.

Bhooma Aravamuthan, MD, DPhil / Washington University, St. Louis, MO

Lawrence C. McHenry: An Award for the History of Neurology

Eduardo Benarroch, MD, DSci / Mayo Clinic, Rochester, MN

Clinical Research Training Scholarship in Tourette Syndrome

Sponsored by the American Academy of Neurology and endowed by Kyowa Pharmaceutical, Inc., Lineberry Research, Quintiles, Dr. Dennis Gillings, and VelaPharma.

Patricia Sikorski, PhD / George Washington University, Washington, WA

Clinical Research Training Scholarship in Parkinson's Disease

Lauren Hammer, MD, PhD / University of California, San Francisco, San Francisco, CA

Jon Stolk Award in Movement Disorders for Young Investigators

Sponsored by the American Academy of Neurology and National Multiple Sclerosis Society and made possible through a special contribution from the John Dystel Multiple Sclerosis Research Fund at the National Multiple Sclerosis Society.

Xavier Montalban, MD, PhD / Vall Hebron University Hospital-Multiple Sclerosis Centre of Catalonia, Barcelona, Spain

David Burkholder, MD / Mayo Clinic, Rochester, MN

Lawrence M. Brass Stroke Research Award Funded by the American Heart Association and the American Brain Foundation, in collaboration with the American Academy of Neurology.

Alexandra Czap, MD / University of Texas-Houston, Houston, TX

McKnight Clinical Translational Research Scholarship in Cognitive Aging and Age-Related Memory Loss Funded by the McKnight Brain Research Foundation through the American Brain Foundation, and the American Academy of Neurology.

Michael Kleiman, PhD / University of Miami School of Medicine, Miami, FL Sarah Szymkowicz, PhD / Vanderbilt University Medical Center, Nashville, TN

Medical Student Essay Awards: Extended Neuroscience Sponsored by the American Academy of Neurology.

Ari Vandersluis / Ohio University Heritage College of Osteopathic Medicine, Columbus, OH

Medical Student Essay Awards: G. Milton Shy Sponsored by the American Academy of Neurology.

Carly Olszewski, BS / Wake Forest School of Medicine, Winston-Salem, NC Continued on page 24

›

MEMBERSHIP Celebrate These 2022 AAN Award Recipients continued from page 23 Medical Student Essay Awards: Roland P. Mackay Sponsored by the American Academy of Neurology.

Sponsored by the American Academy of Neurology and supported by friends of Dr. Jerome Posner.

Not given in 2022

Not given in 2022

Medical Student Essay Awards: Saul R. Korey

Neuro-oncology Scientific Award

Sponsored by the American Academy of Neurology.

Sponsored by the American Academy of Neurology and supported by friends of Dr. WK Alfred Yung.

Margo Peyton, BA / Johns Hopkins School of Medicine, Baltimore, MD

Elizabeth Gerstner, MD / Massachusetts General Hospital, Boston, MA

Michael S. Pessin Stroke Leadership Prize

Neuroscience Research Prize

Sponsored by the American Academy of Neurology and endowed by Dr. Pessin’s family, friends, and colleagues.

Sponsored by the American Academy of Neurology.

Jessica Guo / Ward Melville High School, East Setauket, NY

Amy Yu, MD, MSc / University of Toronto, Toronto, Ontario, Canada

Archita Khaire / North Carolina School of Science and Mathematics, Charlotte, NC

Mitchell B. Max Neuropathic Pain Award

Samuel Wu / Dublin High School, Dublin, CA

Sponsored by the American Academy of Neurology and endowed by the United States Cancer Pain Relief Committee, the Mayday Fund, and friends of Dr. Mitchell Max. John Markman, MD / University of Rochester, Rochester, NY

Movement Disorders Research Award Sponsored by the American Academy of Neurology, the Parkinson’s Foundation, and the American Academy of Neurology Movement Disorders Section and endowed by the Parkinson’s Foundation.

Charles Adler, MD, PhD / Mayo Clinic Arizona, Scottsdale, AZ

Neuroendocrine Research Award Sponsored by the AAN and supported by friends of Dr. Andrew Herzog.

Neuroscience Research Prize in Child Neurology Sponsored by the American Academy of Neurology and the Child Neurology Society.

Aliya Fisher / Bronx High School of Science, New York, NY

Norman Geschwind Prize in Behavioral Neurology Sponsored by the American Academy of Neurology and endowed through Dr. Geschwind’s family, friends, and colleagues; Pfizer Inc; and the Society for Behavioral and Cognitive Neurology.

Julio Rojas-Martinez, MD, PhD / University of California San Francisco, San Francisco, CA

Deborah Gustafson, PhD, MS / State University of New York Downstate Health Sciences University, Brooklyn, NY

Practice Research Training Scholarship

Neuroscience Research Training Scholarship

Kyra O'Brien, MD / University of Pennsylvania, Philadelphia, PA

Funded by the American Academy of Neurology.

Promoting Diversity, Equity, and Inclusion in Autism Research

Sattar Khoshkhoo, MD / Brigham and Women's Hospital, Boston, MA Sinifunanya Nwaobi, MD, PhD / University of California-Los Angeles, Los Angeles, CA

24

Neuro-oncology Investigator Award

AANnews • April 2022

Funded by the American Academy of Neurology.

Funded by the American Brain Foundation in collaboration with the American Academy of Neurology.

Audrey Brumback, MD, PhD / University of Texas at Austin, Dell Medical School, Austin, TX

Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases Sponsored by the American Academy of Neurology and the American Brain Foundation and funded through the philanthropy of the Potamkin family.

Vladimir Hachinski, CM, MD, DSc, FRCPC, FCAHS, FAHA, FAAN, FRSC / London Health Sciences Centre, London, Ontario, Canada

Richard Olney Clinician Scientist Development Award in ALS Funded by The ALS Association and American Brain Foundation in collaboration with the American Academy of Neurology.

Lauren Kett, MD, PhD / Massachusetts General Hospital, Boston, MA

Robert Katzman, MD, Clinical Research Training Scholarship in Alzheimer's and Dementia Research Funded by the Alzheimer's Association and American Brain Foundation in collaboration with the American Academy of Neurology.

Jeffrey Motter, PhD / Research Foundation for Mental Hygiene, Inc., New York, NY

Scientific Breakthrough Award Sponsored by the American Brain Foundation Stephen L. Hauser, MD / University of California, San Francisco, CA

Sheila Essey Award: An Award for ALS Research Presented by the AAN and the ALS Association and supported through the philanthropy of the Essey family through the American Brain Foundation and the ALS Association.

Matthew Kiernan, MBBS (Honours), PhD, DSc, FRACP, FAHMS / Brain and Mind Centre, University of Sydney, Sydney, Australia

Sleep Science Award Sponsored by the American Academy of Neurology and the Sleep Section and endowed by Cephalon, Inc. Louis Ptacek, MD / University of California San Francisco, San Francisco, CA

Susan S. Spencer, MD, Clinical Research Training Scholarship in Epilepsy Funded by the American Epilepsy Society, Epilepsy Foundation, and American Brain Foundation in collaboration with the American Academy of Neurology.

Regan Lemley, MD / Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Wayne A. Hening Sleep Medicine Investigator Award

Neurology ® Resident & Fellow Section Writing Award

Sponsored by the American Academy of Neurology and endowed by UCB, Inc., Lilly USA, Elite Home Medical & Respiratory, Inc., Raleigh Neurology Associates, and friends of Dr. Wayne A. Hening.

A. Chris Espinoza, MD; Melissa A. Wright, MD; Meghan S. Candee, MD, MS; Cristina Trandafir, MD, PhD; and Gary R. Nelson, MD / Department of Pediatrics, Division of Pediatric Neurology, University of Utah, Salt Lake City, UT. Resident & Fellow Editorial Team for the article “Child Neurology: Late-onset Vitamin B6–Dependent Epilepsy Identified by Rapid Genome Sequencing”

John Werner, MD, PhD / Uniformed Services University, Bethesda, MD

SCHOLARSHIPS Futures in Neurological Research Scholarship to the Annual Meeting

Katie Holroyd, MD / Brigham and Women’s Hospital, Boston, MA

Sponsored by the AAN Clinical Research Subcommittee.

Joey Hsu / University of Pittsburgh School of Medicine, Pittsburgh, PA

David Acero-Garces / Johns Hopkins University, Baltimore, MD

Natalia Chunga Iturry, MD / University of Rochester Medical Center, Rochester, NY

Shane Arsenault, MD / Memorial University of Newfoundland, St. John’s, NL

Leon Jekel / Yale University, New Haven, CT

Alexandra Brooks, PhD / Northeast Ohio Medical University, Rootstown, OH Tzu-Ying Chuang, MD, PhD / Thomas Jefferson University Hospital, Philadelphia, PA Andrew Dhawan, MD / Cleveland Clinic, Cleveland, OH J. Vivian Dickens, PhD / Georgetown University, Washington, DC Susana C. Dominguez Penuela, MD / Johns Hopkins University School of Medicine, Baltimore, MD John Erdman / Icahn School of Medicine at Mount Sinai, New York, NY David Fischer, MD, PhD / University of Alabama at Birmingham, Birmingham, AL Milagros Galecio-Castillo, MD / University of Iowa, Iowa City, IA Virginia Gao / Weill Cornell Medical College, New York, NY Mekka Garcia, MD / NYU Langone, New York, NY John Gatti / Johns Hopkins University School of Medicine, Baltimore, MD

Andrea Jones, MD, PhD / University of British Columbia, Vancouver, British Columbia Jonas Kruse / TCU and UNTHSC School of Medicine, Fort Worth, TX Jamie McDonald, MD / Stanford University, Stanford, CA

Kanika Sharma, MD, MBBS / National Institutes of Health / National Institute of Neurologic Disorders and Stroke, Bethesda, MD Jaime Shoup, MD / University of Louisville, Louisville, KY Dinesh Keran Sivakolundu, MD, PhD / Yale New Haven Hospital, New Haven, CT Christy Soares / Florida State University College of Medicine, Tallahassee, FL Isha Srivastava, MD, PhD / Stanford University, Stanford, CA Alice Tao / Weill Cornell Medical College, New York, NY

Sara Merkaj / Yale School of Medicine, New Haven, CT

Nefize Turan, MD / Tufts Medical Center, Boston, MA

Kimberly O'Neill, MD / Montefiore Medical Center, Bronx, NY

International Scholarship Award

Eleni Papadopoulos / Rowan University School of Osteopathic Medicine, Stratford, NJ Jorge Patino, MD / The University of Texas Health Science at Houston, Houston, TX Gabriel Cassinelli Petersen / Yale School of Medicine, New Haven, CT Rohan Rao / University of Cincinnati College of Medicine, Cincinnati, OH Sanskriti Sasikumar, MD / University of Toronto, Toronto, Ontario Fatemeh Seifar, MD / Emory University, Atlanta, GA

Sponsored by the American Academy of Neurology International Subcommittee.

Chandana Bhagwat, MBBS, MD / PGIMER, Chandigarh, Chandigarh, India Akshay Deepak, MD, MBBS / Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India Aravind Ganesh, MD, DPhil, FRCPC / University of Calgary, Calgary, Alberta, Canada Giulia Giacomucci, MD / University of Florence, Italy Helena Gosseye, MD / Antwerp, Antwerpen, Belgium

Continued on page 26

›

MEMBERSHIP Celebrate These 2022 AAN Award Recipients continued from page 25 Maurizio Grassano, MD / University of Turin, Turin, Italy

Melanie Lara Sánchez, MD / Fleni, Buenos Aires, Capital Federal, Argentina

Juan Vazquez / Albert Einstein College of Medicine, Bronx, NY

Elisabeth Hendrickx Van de Craen, MD / Center for Molecular Neurology, VIB-Uantwerpen, Antwerpen, Belgium

Dario Saracino, MD / Paris Brain Institute / Sorbonne Université / Hôpital Pitié-Salpêtrière, Paris, France

Medical Student Experience at the Annual Meeting Scholarship

Akarin Hiransuthikul, MD / Chulalongkorn University, Bangkok, Thailand

Damaris Vazquez Guevara, MD / Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico

Zi-Yue Liu, MD / Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China Akintomiwa Makanjuola, MD, MBBS / University College Hospital, Ibadan, Nigeria Monica Margoni, MD / San Raffaele Hospital, Milan Juan José Méndez Gallardo, MD / Instituto Nacional De Neurologia Y Neurocirugia, Ciudad De México, Mexico Saloua Mrabet, MD / Razi University Hospital, Mannouba, Tunisia Oladotun Olalusi, MD, NSr / UCH, Oyo, Oyo, Nigeria Aldanica Olano, MD / The Medical City, Pasig City, Philippines Fizza Orooj, MRCP / Shifa International Hospital, Neurology Division, Islamabad, Pakistan Jasmine Parihar, MBBS, MD, DM / Consultant Neurologist Yatharth Hospital, Noida, India Thomas Parker, MD / Imperial College London, London, United Kingdom Harini Pavuluri, MD, DM / Andhra Pradesh, India Ratnayake Mudiyanselage Gimhani Dheemantha Ratnayake, MD, NSr / National Hospital of Sri Lanka, Kolonnawa, Western Province, Sri Lanka Nikolai Gil Reyes, MD / University of Toronto-Toronto Western Hospital, Toronto, Ontario, Canada Roberto Rodriguez-Rivas, MD / Instituto Nacional De Neurologia y Neurocirugía, CDMX, Mexico

26

Ana Claudia Villegas, MD / Hospital Fundacion Santa Fe, Cambridge, MA Manav Vyas, MD, MBBS, MSc, PhD / University of Toronto, Toronto, Ontario, Canada Miranda Mengyuan Wan, MD / Department of Clinical Neurosciences, Calgary, Alberta, Canada Tim Woelfle, MD, MSc / Neurology, University Hospital Basel, Switzerland, Basel, Switzerland Ahmed Yassin, MD / Jordan University of Science and Technology, Irbid, Jordan Tracy Ming-Chun Yu, MD, MPH / Cardinal Tien Hospital, New Taipei City, Taiwan Yang Zheng, MD, PhD / First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China Charlotte Zuurbier, MD / University Medical Center Utrecht, Wognum, Netherlands

Medical Student Diversity Scholarship Supported in part by The AbbVie Foundation.

Desmond Bhimull / Stony Brook Medical School, Stony Brook, NY Katsiah Cadet / Penn State College of Medicine, Hershey, PA Vivian Chioma / Medical University of South Carolina, Charleston, SC Tracy De Los Santos / University of California, Davis School of Medicine, Sacramento, CA Isaac Domenech / University of Kentucky College of Medicine, Lexington, KY Tochi Eboh / Texas Tech School of Medicine, Amarillo, TX

Katarina Rukavina, MD / Parkinson's Foundation Centre of Excellence at King's College Hospital and King’s College London, London, United Kingdom

Tyler Nichols / Indiana University School of Medicine, Indianapolis, IN

Alvee Saluja, MBBS, MD, DM / Lady Hardinge Medical College, New Delhi, Delhi, India

Aldwin Soumare / PCOM-GA, Suwannee, GA

AANnews • April 2022

Maikerly Reyes / Sidney Kimmel Medical College, Philadelphia, PA

Nabeel Ahmad, MSEd / University of Houston College of Medicine Sanya Ahmed / SUNY Downstate College of Medicine Reniba Babu, BA / UT Health Houston (McGovern Medical School) Mara Bahri, MSc / The Ohio State University College of Medicine Isabella Buccieri / University of Illinois College of Medicine Maryellen Campbell, BA / Charles E. Schmidt College of Medicine at Florida Atlantic University Alecca Como, BS / Oakland University William Beaumont School of Medicine Kyle Distler / Edward Via College of Osteopathic Medicine Alexis Domeracki, MS / Duke University Alyssa Margaret Edwards, MPH / Case Western Reserve University School of Medicine Thomas Gossard / Creighton University Medical School Sarah Grosser, MA / Stony Brook University Erin Hedglen, MA / Uniformed Services University of the Health Sciences Lauren Hurst / The Ohio State University College of Medicine Meha Joshi, BA / Wright State University Boonshoft School of Medicine Guldamla Kalender, BA / University of Minnesota Skyler Kanegi, BA / UT Health San Antonio Ema Karakoleva, BS / Penn State College of Medicine Hannah Marie Kelly, BS / Case Western Reserve University School of Medicine Jeehyun Kim / University of Rochester School of Medicine & Dentistry Thalia Medina Rodriguez / San Juan Bautista School of Medicine Pranav Mirpuri, BS / Chicago Medical School

Anna Moshkovich, BS / Rush Medical College

Wang Pong Chan, BA, BS / Boston University School of Medicine

Bowen Song / Wayne State University School of Medicine

Jordan Andrew Nasenbeny, MSc / University of Illinois College of Medicine, Peoria

Olivia Cummings / Indiana University School of Medicine

Sean Laxamana Thompson, BS / Medical University of South Carolina

Karam Gagi, BS / Michigan State College of Human Medicine

Adam Uppendahl / Sidney Kimmel Medical College

Mirna Hennawy, BSc / University of British Columbia

Ammar Lamak Ujjainwala / University of Illinois College of Medicine at Peoria

Bryson Hewins, MS / Uniformed Services University of the Health Sciences

Peter Vo / California Northstate University

Joy C. Josephs Njiribeako, BS / Texas Tech University Health Science Center Ai Aileen Ohno, BS / California University of Science and Medicine Taylor Maxwell Parker, BA / University of Florida College of Medicine Bianca Haley Persaud, BA / The Warren Alpert Medical School of Brown University Mauricio Bier Pinto, BS / The Warren Alpert Medical School of Brown University

Justin Ho, MBS / Tufts University School of Medicine Emily Hoegh, BS / University of Arizona College of Medicine-Tucson

Audrey Wack, BA / Boston University School of Medicine Ryan Conor Williams, BS / Stony Brook University

Yajur Iyengar / University of TorontoTemerty Faculty of Medicine

Morgan Young / Lincoln Memorial University DeBusk College of Osteopathic Medicine

Sharmila Raju, MS / Chicago Medical School

Nimansha Jain, BA / Washington University in St. Louis School of Medicine

Zahra Zhu, BA / Penn State College of Medicine

Anne Sophie Reisch / University of Connecticut School of Medicine

Kinnari Karia / The University of Iowa Carver College of Medicine

Eric Zuberi / University of Louisville

Michaela Reuter / University of Cincinnati College of Medicine

Cheryne Kim / Oakland University William Beaumont School of Medicine

Rikki Samuel / University of California Davis School of Medicine

Yee Jung Kim, BS / Weill Cornell Medical College

Alizeh Shamshad, BS / The Warren Alpert Medical School of Brown University

Jonas Kruse / TCU and UNTHSC School of Medicine

Rishi Sharma, BS / University of Minnesota

Deepika Kurup, AB / Stanford University School of Medicine

Lauren Danielle Pomerantz / Penn State College of Medicine

Rui Tang, MA / Texas Tech University Health Sciences Center El Paso Salvatore Giovanni Volpe, MA / SUNY Downstate College of Medicine Alex David Waldman, BS / Emory University, National Institutes of Health, University of Oxford Zachary Weinstock, BS / University at Buffalo-Jacobs School of Medicine & Biomedical Sciences Ethan Daniel Zerpa-Blanco, MS, NRP / Lincoln Memorial University-Debusk College of Osteopathic Medicine

Medical Student Scholarship to the Annual Meeting

Isaac W. Lamb / Indiana University School of Medicine Nancy Le / California Northstate University Jay B. Lusk, BSc / Duke University Marina Motina, MS / Texas College of Osteopathic Medicine

Neuroscience is™… Rewarding Internship Mia T. Minen, MD, FAAN / NYU Langone Health, New York, NY Jennifer Lauren Thomas, MD / UT Southwestern Medical Center, Dallas, TX

Resident Research Scholarship Sponsored by the Clinical Research Subcommittee.

Joel Neves Briard, MD / Universite De Montreal, Montreal, Quebec Virginia Gao, MD, PhD / New York Presbyterian-Weill Cornell Medicine, New York, NY

Sophia Gillian Musacchio, BA / Medical College of Wisconsin-Milwaukee

Alice Hawkins, MD / Mount Sinai Health System, New York, NY

Samantha Paige Myers, BS / University of Rochester

Resident Scholarship to the Annual Meeting

Jackson Narrett, MS / University of Virginia Namita Patel, HBSc / Virginia Commonwealth University School of Medicine

Rachel Adlis / UT Health San Antonio Long School of Medicine

Srinath Ramanan, BS / UConn School of Medicine

Jennie Burns, BS / University of Arkansas for Medical Sciences

Muslima Sonia Razaqyar, BA / UT Health SA

Magalie Carey, BSc / University of Vermont Larner College of Medicine

Kevin Alexander Soltany, BA / Wake Forest School of Medicine

Leah Shabo, BS / University of Virginia

Ahmed Abbas, MD / Southern Illinois University School of Medicine Neurology Residency Program Diana Andino, MD / Loyola University Medical center Katrina Badiola, MD / University of Connecticut Neurology Residency Program Ahmad Ballout, MD / Hofstra North Shore-LIJ School of Medicine Program

Continued on page 28

›

MEMBERSHIP Celebrate These 2022 AAN Award Recipients continued from page 27 Richard Baron, MD / Stanford University Benjamin Beland, MD / University of Calgary Megan Bone, MD / University of Texas Southwestern Medical Center Andrew Breithaupt, MD / UCSF Joel Neves Briard, MD / Université de Montréal Erika Chandler, MD / University of Louisville Child Neurology Zaheerud Cheema, MD / University at Buffalo Xing Dai, MD / Rhode Island Hospital, Neurology Department Hasan Dawood, MD / Loma Linda University-Dept of Neurology Anish Deshmukh, MD / University of Utah Medical Center

Mattia Rosso, MD / Medical University of South Carolina

Alissa Kasunich, MD / University Hospitals Cleveland Medical Center/ Case Western Reserve University

Vivek Satyasi, MD / Penn State Health Hershey Medical Center

Gaurav Kathuria, MD / Memorial Healthcare System Diana Li, MD / URMC Neurology Jennifer Liu, MD / Massachusetts General Hospital Luis Manrique-Trujillo, MD / University of Illinois College of Medicine at Peoria Austin Momii, MD / Cedars-Sinai Medical Center Jonathan Morena, DO / The Ohio State University Fady Mousa-Ibrahim, DO / Loyola University Medical Center Department of Neurology

Ezgi Saylam, MD / Nationwide Children's Hospital Joseph Seemiller, MD / Geisinger Medical Center Keval Shah, MD / Detroit Medical Center / Wayne State University Sha'ray Shaw, MD / University of Missouri Kansas City Risako Shirane, MD / Icahn School of Medicine at Mount Sinai Abdullah Shoaib, MD / UT Southwestern Maria Shoaib, MD / OU Neurology

Christopher Nguyen, MD / LAC+USC

Devin Simon, MD / Michigan State University/Sparrow Hospital

Hannah Noah, MD / University of Vermont Medical Center

Jasmine Singh, MD / Loyola University Medical Center

Matthew Feldman, MD / Jackson Health System

Teryn Nogles, MD / Virginia Commonwealth University Health System

Crystal Sosa, MD / WFBH

Keiko Fukuda, MD / UPMC Department of Neurology

Mirza Omari, MD / New York University, Langone Medical Center

Lucy Gee, MD, PhD / Jefferson Neurology

Preethy Pankaj, MBBS / University of Washington Medical Center

Keli Tahara, MD / Los Angeles County Harbor-UCLA Medical Center

Hemali Patel, DO / UC Davis Health

Mangayarkarasi Thandampallayam Ajjeya, MBBS / University of Kentucky

Therese Dunne, MD / Rush University Medical Center Levi Dygert, MD / New York University Langone Health

Veronica Moreno Gomez, MD / University of Oklahoma Health Sciences Center Karina Gonzalez Otarula, MD / University of Iowa Helena Gossye, MD / VIB CMN

Rachel Pauley, MD / NYU Langone Health Mauricio Perez Davila, MD / UTMB Health

Olivia Gutgsell, MD / University of Michigan

Lee Pfaff, MD / SUNY Upstate Medical University

Harjot Hansra, MD / Barrow Neurological Institute

Parakash Pratibhu, MD / University of Mississippi Medical Center

Shruthi Harish, MBBS / Einstein Medical Center Daniel Harrison, MD / Mass General Brigham Dana Ionel, DO / University of Kentucky Goun Je, MD, PhD / UMass Medical School Sung Jeon, MD / University of Colorado School of Medicine

28

Manish Karamchandani, MD / Medical University of South Carolina

AANnews • April 2022

Meghna Rajaprakash, MD / Kennedy Krieger Institute, Neurodevelopmental Disabilities/Child Neurology Sandra Reiter-Campeau, MD / McGill University Roysten Rodrigues, MD / University of Louisville School of Medicine

William Spears, MD / Boston Medical Center Brian Stamm, MD / Northwestern University

Neeharika Thottempudi, MD / UTMB Health Mariam Tsikvadze, MD / University of Connecticut Andrew Voyiadjis, MD / Tulane University Greer Waldrop, MD / Columbia University-NYP Zehui Wang, MD / New York Presbyterian/ Weill Cornell Medicine Philip Yeung, MD/ Stony Brook 

EVENTS There’s Still Time to Register for the Upcoming Virtual Annual Meeting continued from cover Highlights include: 40+ unique courses and sessions featuring live Q&A 7 program tracks for researchers, trainees, and those interested in wellness, career development, and clinical practice, Spanish language programming, and multidisciplinary case conferences.

Plenary sessions with live fireside chats Quick Learning sessions—start out each day with a brief overview of the day’s highlights Edutainment, poster hall, and more Access to session recordings through May 14, 2022 Upgrade and Extend Your Access Through March 1, 2023!

Extend your access to most recordings from both the in-person meeting in Seattle and the virtual option through March 1, 2023, when you upgrade to Platinum registration! Visit AAN.com/AM to learn more. 

Seattle: April 2 –7 Virtual Experience: April 24–26

Registration Opens Later This Month for New Summer Conference continued from cover Highlights will include:

Opening and closing keynote addresses Panel Q&A Poster sessions Exhibit hall Case studies Year in review talks on headache, multiple sclerosis, epilepsy, dementia, movement disorders, and stroke

San Francisco 2022

Visit AAN.com/SummerConference to learn more and to secure your early registration savings by May 26. 

Autoimmune Neurology Abstracts Due May 3

Abstracts showcasing the latest autoimmune neurology research are now being accepted until 11:59 p.m. CT on May 3. Abstract fees are $50 for AAN members, $100 for nonmembers, and free for students and residents.

Visit AAN.com/SummerConference to learn more and to submit. 

AANnews • April 2022

29

AMERICAN BRAIN FOUNDATION Hauser to Be Honored with Scientific Breakthrough Award at Commitment to Cures Gala Stephen L. Hauser, MD, of the University of California in San Francisco, will be presented with the American Brain Foundation’s Scientific Breakthrough Award during the Foundation’s Commitment to Cures Gala on April 6 at the Hyatt Regency Seattle during the AAN Annual Meeting.

The Scientific Breakthrough Award honors an individual or group whose research has led to meaningful advances for the care of patients living with neurologic disease. “Hauser’s research has advanced our understanding of the genetic basis, immune mechanisms, and treatment of multiple sclerosis,” said Robert C. Griggs, MD, FAAN, chair of the Foundation's Research Advisory Committee. “His work led to the development of B cell therapies for MS patients, representing a powerful new approach for progressive forms of the disease.

His 40-plus year, career-long commitment has changed the landscape of treatment for what has been, until now, a relentlessly progressive form of MS.” “I thank the American Brain Foundation for this wonderful honor, which I accept with gratitude and on behalf of the many others who participated in this 40-year journey—colleagues across national borders, industry partners who took risks on a disease mechanism judged by many as implausible, funders including the Ad—Half NationalPage MS Society andAN the NIH, and private NCC: 21 Career Center Ads Horizontal> donors who believed in novel scientific directions,” said Hauser.

Placed in AANnews 8.25 x 5.25 +0.125 bleed, 4C like to thank the thousands of patients who “I’d especially

trusted us and agreed to participate in our research. I hope that this recognition will also underscore the importance of bringing medical care and science together in a common effort to speed the development of treatments for disabling brain diseases.”

Hauser

The Commitment to Cures Gala galvanizes the neurology community around the crucial need to support research. In addition to Hauser accepting his award, this year’s event will feature inspiring stories from people living with brain disease, important updates on the latest research studies, and special guests, including actor and comedian Seth Rogen and his wife, Lauren Miller Rogen, and Susannah Cahalan, the New York Times bestselling author of Brain on Fire. Tickets are still available at AmericanBrainFoundation.org for those interested in attending the event virtually. All ticket sales and proceeds go to funding brain research.

Learn more about the American Brain Foundation’s 2022 awards and recipients at AmericanBrainFoundation.org/awards. 

Where the Top Jobs and Top Talent Connect!

From first job to career shift, get access to the latest openings, candidate CVs, and timely resources to seal the deal.

Go right to the top at Careers.AAN.com!

Careers.AAN.com

Visit the AAN’s Neurology Career Center to view hundreds of additional jobs and sign up for customized, confidential notifications when positions of interest are added.

Henry Ford Health System Chair—Department of Neurology —Henry Ford Medical Group—Detroit, Michigan Henry Ford Medical Group (HFMG), one of the nation’s largest group practices, is seeking a Department Chair of Neurology.

It is comprised of hospitals, medical centers, and ambulatory clinics. The Neurology Chair will provide executive leadership for Neurology at Henry Ford Hospital and HFMG as well as strategic input and planning for neurological services throughout Henry Ford Health System (HFHS). This position will report directly to the Chief Executive Officer of the HFMG. The Department of Neurology at Henry Ford has strong local, regional, national, and international recognition for excellence in clinical care, clinical and translational research, and education. This position will partner with an administrative leader to lead the Department of Neurology. The Neurology Department currently provides care at 3 hospitals and 9 outpatient clinic sites with the intent of supporting the continued expansion and integration of Neurology in a collaborative and fully integrated model when possible. The Department consists of 59 Neurologists, 13 researchers, 13 APPs, 21 RN ’s, 17 MA and 4 support staff in addition to 24 residents and 7 fellows. The Chair will be a practicing member of the Neurology Department. We are actively recruiting a physician leader to continue our tradition of success! The Neurology Department Chair knows, understands, incorporates, and demonstrates the mission, vision, and values of HFMG and HFHS in leadership behaviors, practices, and decisions.

The Chair also models behaviors, which support continuous learning and empowerment through team leadership. The Chair, in conjunction with relevant Division Heads, will also be responsible for academic activities of all physicians within Neurology. The Chair will work in collaboration with the Chief Medical Officers within each market to meet market goals in Neurology where those services are offered.

Principle Duties and Responsibilities: Oversight and responsibility of care delivery within HFMG Neurology.

Collaborate with leaders across the system to standardize and improve quality and safety metrics, achieve growth strategy targets, and promote an inclusive workplace culture. Provides support and assists with the development of research and educational programs in collaboration with Michigan State University. Monitors and manages clinical productivity as well as oversees the development of common performance measures, clinical protocols and improvement plans across the Neurology Department.

Qualifications: Doctorate degree in Medicine and Neurology residency required. Must be licensed or qualified for licensure to practice medicine in the State of Michigan and be Board Certified in a Neurology-related specialty. Strong clinical experience as a Neurologist. MBA or MHA preferred. Ten (10) or more years of clinical and executive leadership experience, including responsibility for fiscal and medical staff management. Experience in a large, advanced, complex health system is essential. Experience within an integrated care system that includes multiple hospitals, a pluralistic medical staff. A proven track record in improving quality and safety in a complex health system is required. Must be a leader champion of quality.

Thorough knowledge and understanding of current trends in health care, including physician hospital relations, physician practice models, access issues, quality improvement processes, clinical information systems, and the implications of changing health care environment for medical credentialing are essential.

Excellent interpersonal communication and presentation skills. Advocate for organizational values and commitment to justice, equity, diversity, and inclusion.

Henry Ford offers a comprehensive benefits package that includes medical/vision, dental, disability, life, 403(b), 457 (b), professional development allowances, moving expenses, and CTO. For additional details please visit Chair—Department of Neurology—Henry Ford Health System Careers (selectminds. com) https://henryford.referrals.selectminds.com/jobs/ chair-department-of-neurology-63244?et=3blxXiCIn The Henry Ford Medical Group is one of the nation’s largest and most experienced group practices, with 1,900 physicians and researchers in more than 40 specialties. The System also includes six hospitals, Health Alliance Plan (a health insurance and wellness company), Henry Ford Physician Network, a 150-site ambulatory network, and many other health-related entities throughout southeast Michigan, providing a full continuum of care. The System's flagship, Henry Ford Hospital in Detroit, is a Level 1 Trauma Center recognized for clinical excellence in cardiology, cardiovascular surgery, neurology and neurosurgery, orthopedics, sports medicine, multi-organ transplants and cancer treatment.

With more than 30,000 employees, Henry Ford Health System is the fifth-largest employer in metro Detroit, and among the most diverse. Founded in 1915 after consultations with physicians at Johns Hopkins Hospital and the Mayo Clinic, the Henry Ford Medical Group has established itself as one of the premier group practices in the nation. For more than 100 years, the Henry Ford Medical Group has fostered innovation and advancement in patient care, education and research while encouraging improvement in technology and patient care processes. The Henry Ford Medical Group has established itself as a leader in healthcare by excelling in three key areas: Clinical care: Ranked in the 99th percentile of all group practices. Research: We are in the top 6 percent of National Institutes of Health-funded institutions. Education: We are one of the largest post-graduate medical education enterprises in the country—one-third of all physicians in Michigan receive training at Henry Ford. Academic Affiliations: Michigan State University School of Medicine (MSU SOM) and Wayne State University School of Medicine (WSU SOM).

Please forward your CV and letter of interest to Laura Settles via the link or by emailing lsettle2@hfhs.org. I may also be reached by phone at (313) 282-4747. Thank you in advance for your consideration. Laura Settles, FASPR—Equal Employment Opportunity / Affirmative Action Employer Henry Ford Health System is committed to the hiring, advancement and fair treatment of all individuals without regard to race, color, creed, religion, age, sex, national origin, disability, veteran status, size, height, weight, marital status, family status, gender identity, sexual orientation, and genetic information, or any other protected status in accordance with applicable federal and state laws.

New Division Director of Neurohospital Medicine at Stony Brook—Faculty Opportunity Also Available Merritt Hawkins—Renaissance School of Medicine at Stony Brook University—Stony Brook, New York The Department of Neurology in the Renaissance School of Medicine at Stony Brook University is establishing a formal neurohospitalist program in July 2022. Considered a flagship research institution and destination academic medical center for central Long Island, Stony Brook University is seeking a new Division Director of Neurohospital Medicine to lead this critical and dynamic program. The Neurohospitalist Division Director will oversee a division consisting of three full-time faculty and multiple advanced practice providers. Division faculty manage a broad range of neurologic and medical conditions with complimentary subspecialty training in other inpatient-oriented subspecialties, such as epilepsy, stroke, neuroimmunology, and critical care. He/she will liaise with

the Section Chiefs of Vascular Neurology, Neurocritical Care, Epilepsy, and leadership from the Department of Emergency Medicine to manage and enhance quality standards of the inpatient and consultative service lines. In addition, Division Chief and faculty will collaborate on initiatives that contribute to the overall mission of the division, department, and institution by improving quality metrics, safety, patient satisfaction, and length of stay. Faculty should also develop and deliver high-quality instruction and clinical oversight to our dedicated team of advanced practice providers and trainees in our fellowship, residency, and clerkship programs.

Faculty within this division will have clinical and academic interests that promote the overall mission of this division and the department (e.g., quality measurement/improvement, hospital operations, patient-centered care, or resident/ student education). Opportunity Highlights—Place your professional stamp on this new Neurohospitalist program in a top-ranked Neuroscience institute, Establish new models of care to include quality metrics, safety, patient satisfaction, and length of stay measures, Opportunity to create new educational programs specific to the Neurohospital space, Research platform and system-wide resources can be harnessed to establish collaborative, scientific research with other leaders in the field of neuroscience, Program is supported by a Level I Trauma Center, Comprehensive Stroke Center, Comprehensive Epilepsy Center, adult and pediatric residencies, and three specialized fellowship programs, Evaluate opportunities to grow the existing teleneurology service provided to affiliate hospitals, Faculty positions available that offer significant protected time for research and subspecialty development. Community Information—Live in Long Island, a beautiful waterfront community that offers a superb quality of living, reasonable New York housing, excellent schools, and an abundance of outdoor recreation in northern Long Island. All this is a short drive to one of the most exciting cities in the world—New York City. Long Island has an overall grade of A and is one of the best places to live in New York (Niche), Visit the Hamptons on the eastern shore, Excellent restaurants, museums, and an aquarium.

To qualify, applicants must be a board-eligible or boardcertified neurologist interested in hospital-based patient care and clinical teaching. Candidates with experience or interest in general and stroke neurology are encouraged to apply. For immediate consideration please inquire with an updated copy of your CV so we can discuss the position by phone. Also, inform me of your best available times to speak.

I look forward to your reply and thank you for your review.

Please do not delay as we anticipate a significant response.

Please contact David King at medcareers@merritthawkins. com or at (866) 406-0269 and reference HNEU-142053.  AANnews® Classified Advertising

he AAN offers a complete package of print, T online, and in-person recruitment advertising opportunities. Visit careers.AAN.com for all AAN options, rates, and deadlines. d copy for the June 2022 print edition of AANnews A must be submitted by May 1, 2022. The same deadline applies to changes/cancellations. he American Academy of Neurology reserves the T right to decline, withdraw, or edit advertisements at its discretion. Every care is taken to avoid mistakes, but the responsibility for clerical or printer errors does not exceed the cost of the ad.

AANnews • April 2022

31

DATES & DEADLINES APRIL 2022 SUN

MON

TUE

WED

THU

3

4

5

6

7

MAY 2022 TUE

WED

JUNE 2022

FRI

SAT

SUN

MON

THU

FRI

SAT

1

2

1

2

3

4

5

6

7

8

9

8

9

10

11

12

13

14

SUN

MON

TUE

5

6

7

WED

THU

FRI

SAT

1

2

3

4

8

9

10

11

10

11

12

13

14

15

16

15

16

17

18

19

20

21

12

13

14

15

16

17

18

17

18

19

20

21

22

23

22

23

24

25

26

27

28

19

20

21

22

23

24

25

24

25

26

27

28

29

30

29

30

31

26

27

28

29

30

APRIL 1

Deadline: UCNS Headache Medicine Certification UCNS.org/HMcertification

APRIL 2–7

Annual Meeting in Seattle AAN.com/AM

APRIL 24–26

Annual Meeting Virtual Experience AAN.com/AM

APRIL 25–26

AAN Neurology Career Center Virtual Career Fair Careers.AAN.com

MAY 1

Application Deadline: UCNS Behavioral Neurology & Neuropsychiatry Certification UCNS.org/BNNPcertification Application Available: UCNS Neuroimaging Certification UCNS.org/NIcertification

MAY 3

Abstract Submission Deadline: AAN Summer Conference: Autoimmune Neurology and Neurology Year in Review AAN.com/SummerConference

MAY 18

Application Deadline: Emerging Leaders, Practice Leadership, and Diversity Leadership Programs AAN.com/Lead

MAY 23–24

Neurology on the Hill AAN.com/NOH

MAY 26

Early Registration Deadline: AAN Summer Conference: Autoimmune Neurology and Neurology Year in Review AAN.com/SummerConference

AANe-news. Because Your Time Is Valuable.

Sent to your email address the second and fourth Wednesday of each month, AANe-news™ delivers the latest top headlines and resources from the Academy so you can quickly scan and connect directly with the information you need to know.

Another members-only solution from your AAN.

JUNE 1

Deadline: UCNS Fellowship Training Accreditation UCNS.org/Accreditation Deadline: UCNS Autonomic Disorders Certification UCNS.org/Adcertification

JUNE 23

Advance Registration and Hotel Deadline: AAN Summer Conference: Autoimmune Neurology and Neurology Year in Review AAN.com/SummerConference